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 1
OVERVIEW 
 
With this work I want to give an explanation of the role of glycolipids in biological 
processes, paying particular attention to their involvement in various biochemical 
mechanisms. 
This thesis will be divided into two sections in which I discuss in the first one, the 
involvement of glycolipids in the process of fertilization and in the second one I will 
pay attention on a new class of glycolipids that might be involved in immunoregulation 
processes. 
In more details in the first section I will provide an overview of the biochemical role of 
sulfogactosylglicerolipid (SGG), present in the sperm head of different mammalian 
species, and its involvement in the process of fertilization. 
Then I will discuss an approach with which one can interfere in this biochemical 
mechanism focusing on the possibility of using a new class of molecules that permit 
not only the inhibition of the fertilization process but that can also act against sexually 
transmitted diseases. In this scenario, then I will focus on the characteristics of 
antimicrobial peptides, in particular on the family of cathelicidin, and on their possible 
application in the inhibition of fertilization, by interaction with SGG, and at the same 
time the prevention of sexually transmitted diseases. 
In the second section I will discuss on a new class of immunomodulating glycolipids 
with an atypical structure, produced by symbiotic bacteria in the marine sponge 
Plakortis Simplex, which releases a unique profile of cytokines. 
In this scenario, then I will talk about simplexide and on the role in which is involved 
in the activation of peripheral blood mononuclear cells (PBMC), and the peculiar 
profile of cytokines released.  
Then I will describe the synthesis of a fluorescent analogue of simplexide which will 
be made to evaluate the subcellular distribution of the glycolipid and to clarify its 
mechanism of action.  
The part of the project related to the study of fertilization process was carried out in the 
laboratory of Prof.ssa Nongnuj Tanphaichitr at the Ottawa Research Institute (OHRI), 
Canada. 
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SECTION I 
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1. INTRODUCTION 
 
 
1.1 Sulfogalactosylglycerolipid (SGG) 
 
1-O-hexadecyl-2-O-hexadecanoyl-3-O-(3’-sulfo-β-D-galactopyranosyl)-sn-glycerol 
(SGG), also known as sulfogalactosylglycerolipid or seminolipid, is a sulfoglycolipid 
substantially present in male germ cells (10 mole% of total lipids) across all the 
mammalian species studied (Bou et al., 2006; Tanphaichitr et al., 2003; Ishizuka et al., 
1973; Kornblatt et al., 1974; Suzuki et al., 1973). SGG consists of a glycerol backbone 
with 3-O-sulfated galactose at the sn-3 position and an alkyl and acyl chain (both 
mainly 16:0) at the sn-1 and sn-2 positions, respectively (Fig. 1) (Ishizuka et al., 1973).   
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Fig. 1 Chemical structures of SGG and SGC. 
 
Sulfogalactosylceramide (i.e., SGC or sulfatide), which can be structurally referred to 
SGG, is a major lipid component of the myelin sheath; it is also found in epithelial 
cells of the kidney and digestive tract as well as in male germ cells of lower vertebrates 
and invertebrates. SGC has the same galacto carbohydrate moiety as SGG but it has 
ceramide as a lipid backbone, unlike SGG (Fig. 1).   
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1.2 Biosynthesis of SGG and SGC 
 
SGG and SGC have identical polar head groups but different lipid backbones (i.e., 1-O-
hexadecyl 2-O-hexadecanoyl glycerol and ceramide, respectively). The biosynthesis of 
SGC, occurring mainly in the brain, involves two enzymes: UDP-galactose: ceramide 
galactosyltransferase (CGT; EC 2.4.1.62) and cerebroside sulfotransferase (CST; EC 
2.8.2.11) (Fig. 2). CGT catalyzes the formation of galactosylceramide (GC) also known 
as cerebroside from ceramide with UDP-galactose as the galactose donor. CST 
catalyzes the synthesis of GC to SGC using 3’-phosphoadenosine -5’-phosphosulfate 
(PAPS) as sulfate donor. Accumulated evidence suggests that the biosynthetic pathway 
of SGG in the testis is similar to that of SGC described in the brain.  Following the 
intratesticular injection of [14C]palmitate, [14C]galactose and [14C]cetyl alcohol, both 
galactosylglycerol (GG) and SGG were radiolabeled, but the radioactivity peak of GG 
preceded that of SGG (Hsu et al., 1983).  This suggested that SGG was synthesized 
from GG via sulfation. In fact, sulfotransferase, localized in the Golgi complexes of 
primary spermatocytes, has been described to catalyze this reaction using PAPS as a 
sulfate donor (Knapp et al., 1973), and the purification of testicular sulfotransferase has 
been reported (Sakac et al., 1992). The enzyme has a molecular mass of 56 kDa and is 
activated by phosphorylation (Sakac et al., 1992). The apparent sulfotransferase 
activity is sharply reduced in the mid-pachytene stage due to the appearance of a small 
molecular weight inhibitor (Lingwood, 1985), identified as a glycosyl phosphoinositide 
(Lingwood et al., 1994). Recently, Honke et al. (Honke et al., 2002) have shown that 
the testicular sulfotransferase is encoded by the same gene as that of cerebroside 
sulfotransferase (CST) present in the brain and kidney. 
 
Fig. 2 Biosynthetic pathway of SGG/SGC. 
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Cst-/- mice genetically depleted of CST lacks SGC in brain, kidney and testis. A 
buildup of GG in testes of these mice also confirms that GG is the precursor of SGG 
(Honke et al., 2002). 
In the metabolic radiolabeling studies of Hsu et al. (Hsu et al., 1983), a small amount of 
alkylacylglycerol (AAG) was detected and therefore AAG was postulated to be 
galactosylated to form GG. Lately, Cgt-/- mice have been generated (Coetzee et al., 
1996a), and in these mice, GG and GC are not found in the testis and the brain, 
respectively (Coetzee et al., 1996a; Fujimoto et al., 2000). Thus, these findings indicate 
that formation of GG from AAG is via the same enzyme responsible for GC formation. 
UDP-galactose, a galactose donor for GC formation in the brain, is also likely to be the 
galactose donor for GG formation in the testis. Unlike CST, testicular CGT has not yet 
been characterized.  However, CGT from the myelinating rat brain has been isolated 
and characterized as a 61-kDa high-mannose glycoprotein (Schulte and Stoffel, 1993). 
Localization of CGT using antibody made against N-terminus of CGT revealed that 
CGT is localized in the endoplasmic reticulum (ER) of CGT-transfected CHO cells 
(Sprong et al., 1998). This result agrees with the presence of the ER retrieval signal 
sequence KKXX at the C-terminal end of the enzyme (Nilsson and Warren, 1994). All 
these results suggest that the synthesis of GG by testicular CGT should also occur in 
this organelle. 
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1.3 Synthetic sites and cellular localization of SGG 
 
Lines of evidence indicate that SGG is actively synthesized in early stages of primary 
spermatocytes during spermatogenesis (Kornblatt et al., 1974; Letts et al., 1978).  Thin 
layer chromatography of isolated testicular glycolipids from 15-20-day-old rats, which 
just have primary spermatocytes appearing in their testes, showed the first appearance 
of SGG; this indicates that SGG is synthesized in primary spermatocytes (Kornblatt et 
al., 1974). To investigate SGG synthesis sites during spermatogenesis, Lett et al. 
(1978) also performed intratesticular injection of [35S] sulfate into adult rats followed 
by isolation of spermatogenic cells using albumin gradient. The results revealed that 
early primary spermatocytes had a high degree of 35S incorporation into SGG whereas 
late primary spermatocytes and spermatids showed minimal corporation of the 
radiolabel.  
Once synthesized in early primary spermatocytes, SGG is transported from its site of 
synthesis via Golgi-derived vesicles towards the plasma membrane, and remains on 
plasma membrane throughout all the subsequent stages of germ cells (Tanphaichitr et 
al., 2003; Klugerman and Kornblatt, 1980; Lingwood et al., 1981; Shirley and 
Schachter, 1980). Indirect immunofluorescence (IIF) of frozen rat testis sections, using 
non-affinity purified rabbit anti-SGG IgG, revealed patchy staining patterns of SGG in 
fixed pachytene spermatocytes, and spermatids, but not in spermatogonia and Sertoli 
cells (Lingwood, 1981). Similar results were also described with loose spermatogenic 
cells released from minced rat testis (Lingwood et al., 1981). Subsequently, Lingwood 
reported SGG immunofluorescent staining in the rat epididymal sperm head 
(Lingwood, 1986). Using affinity purified rabbit polyclonal anti-SGG IgG antibody, 
patchy fluorescent staining patterns of SGG have also been described in live mouse 
primary spermatocytes, round and elongated spermatids, as well as in testicular and 
epididymal sperm (Tanphaichitr et al., 2003; Weerachatyanukul et al., 2003). In 
addition, SGG was shown to exist exclusively on the sperm head anterior plasma 
membrane overlying the acrosomal ridge and postacrosome of mature mouse sperm 
(White et al., 2000), pig sperm (Bou et al., 2006), and human sperm 
(Weerachatyanukul et al., 2001a). Biochemical studies demonstrated that SGG is 
present in isolated head anterior plasma membranes of pig, bull, stallion, and rooster 
sperm at appreciable amounts (i.e., < 10 mole% of total lipids) (Parks and Lynch, 
1992). Since the anterior head plasma membrane is the ZP binding site of the 
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acrosome-intact sperm (Chen and Cardullo, 1994; Kerr et al., 2002; Yanagimachi, 
1994), the results from both immunolocalization and biochemical studies implicate the 
function of SGG in the primary ZP binding. 
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1.4 Degradation of SGG during spermatogenesis 
 
SGG and SGC are postulated to share similarity not only for their synthetic pathway, 
but also for the degradative pathway.  The enzyme responsible for SGC desulfation is 
arylsulfatase A (ASA) (EC 3.1.6.8), a lysosomal enzyme with a molecular mass of 65-
68 kDa. To desulfate sulfoglycolipids, ASA requires a sphingolipid activator protein, 
saposin B, which extract the target sulfoglycolipid from the membrane. The soluble 
sulfoglycolipid-saposin B complex can be recognized by ASA (Kolter and Sandhoff, 
2005; von Figura et al., 2001). Saposin B is derived from its precursor protein, 
prosaposin (O'Brien and Kishimoto, 1991). The fact that ASA and saposin B are 
responsible for physiological degradation of SGC is obtained from phenotypes 
observed in metachromatic leukodystrophy (MLD) patients, genetically deficient in 
either ASA or, more rarely, saposin B. These patients have abnormal accumulation of 
SGC in the brain (the most affected organ) and other visceral organs. Similar but much 
milder phenotypes are also found in ASA deficient (ASA-/-) mice (Molander-Melin et 
al., 2004; Schott et al., 2001). 
Desulfation of SGG to GG by arylsulfatse A (ASA) has been shown in vitro by the 
enzymatic assay using purified human ASA (Fluharty et al., 1974) and isolated boar 
testis ASA (Yamato et al., 1974). Moreover, accumulation of SGG has been observed 
in testes of ASA-/- mice (Schott et al., 2001). Therefore, these findings suggest that SGG 
can be desulfated by ASA in vivo. In addition, accumulation of SGG was observed in 
testes of mice deficient in prosaposin, the precursor protein of saposin B (Tadano-
Aritomi et al., 2003). These results suggest the role of saposin B in facilitating ASA 
action in SGG desulfation in the testis. Although where/how exactly testicular ASA 
functions in SGG degradation has yet to be determined, there is evidence suggesting 
that this action may occur in Sertoli cells. Immunolocalization studies on the testis 
sections revealed that ASA resides not only in the acrosomal process of spermatids but 
also in the lysosomes of Sertoli cells (Moviglia et al., 1982; Weerachatyanukul et al., 
2003). Moreover, prosaposin has been found in lysosomes containing residual bodies 
in Sertoli cells (Morales et al., 1998). This co-presence of ASA and prosaposin implies 
that ASA and saposin B (derived from prosaposin) may act together in the degradation 
of membrane SGG from residual bodies, which are shed from differentiating 
spermatids and phagocytosed by Sertoli cells.   
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1.5 Roles of SGG in male reproduction 
 
SGG and SGC have affinity to a number of cell adhesion proteins, extracellular matrix 
glycoproteins, growth factor, and microorganisms (see the details in Table 1).  
 
 Table 1: SGG/SGC binding molecule 
 
Type SGG/SGC-binding 
molecule 
Note Reference 
Microorganisms 
and surface 
proteins of 
microorganisms 
Escherichia coli 
Enterotoxin b 
A protein in a specific E. coli 
strain that causes diarrhea in 
animals and humans 
(Rousset et al., 1998) 
Mycoplasma 
hominis 
A human pathogen  that is 
transmitted sexually and 
causes infertility 
(Olson and Gilbert, 
1993) 
Circumsporozoite 
proteins* 
A coat protein of malaria 
(plasmodia) sporozoites 
(Pancake et al., 1992) 
Gp120 A surface glycoprotein of the 
human immunodeficiency 
virus (HIV-1) 
(Brogi et al., 1995; 
Brogi et al., 1996) 
Mycoplasma 
pulmonis 
Infertility-related 
mycoplasmas in rodents 
(Lingwood et al., 1990) 
Adhesive 
proteins  
Properdin* A globulin protein found in 
blood serum 
(Holt et al., 1990) 
Antistatin* A saliva protein from the leech 
that inhibits blood coagulation 
(Holt et al., 1989) 
Thrombospondin* A major component of platelet 
α granules 
(Roberts, 1988) 
Von Willebrand 
factor* 
A large plasma glycoprotein 
which binds to platelet and 
promotes platelet adhesion 
(Roberts et al., 1986) 
L-selectin A protein in the selectin family 
found on leukocytes 
(Needham and Schnaar, 
1993; Suzuki et al., 
1993) 
P-selectin (CD62) A protein in the selectin family 
found in granules in 
endothelial cells 
(Bajorath et al., 1994; 
Needham and Schnaar, 
1993) 
Cycotactin A glial glycoprotein that plays 
roles in neural development of 
animals 
(Crossin and Edelman, 
1992) 
Amphoterin (p30)  A 30 kDa protein found in the 
rat cerebellum 
(Mohan et al., 1992) 
Extracellular 
matrix (ECM) 
glycoprotein 
Laminin A major noncollagenous 
glycoprotein of the basement 
membranes 
(Roberts et al., 1985) 
Perlecan (C-terminal 
domain V) 
An abundant proteoglycan 
component of the basement 
membranes 
(Friedrich et al., 1999) 
Components of 
myelin lipid rafts 
Myelin and 
lymphocyte protein 
(MAL) 
A myelin membrane protein 
expressed in central and 
peripheral nerve, and  found in 
rafts of the myelin; A T-cell 
differentiation protein 
(Frank, 2000) 
GC and SGC Major glycolipids of the 
myelin 
(Boggs et al., 2000) 
 10
Intracellular 
chaperone 
Heat shock proteins 
of the 70-kDa 
family (hsp70) 
Molecular chaperones found 
on the surface of bacteria, 
male germ cells, and 
carcinoma cell lines 
(Mamelak and 
Lingwood, 2001) 
Growth factor Midkine A basic heparin-binding 
growth factor in the nervous 
system 
(Kurosawa et al., 2000) 
Anticoagulant Annexin V A calcium-dependent 
phospholipid-binding protein 
(Ida et al., 2004) 
* Contain the amino acid sequence homology , C-S/T-V-S/T-C-G-X-G-X-X-X-R/K-X-R/K (X = any 
amino acid) (Holt et al., 1989) 
 
All these findings suggest that SGG may serve as an adhesion molecule in cell-
cell/extracellular protein interactions during male germ cell development and 
fertilization process.  
In fact, has been shown that SGG is involved in the binding between acrosome intact 
sperm and the ZP and between acrosome-reacted sperm and the egg plasma membrane 
(Ahnonkitpanit et al., 1999; White et al., 2000). Moreover, during the sperm transit in 
epididymis, SGG also serves as a ligand for adsorption of arylsulfatase A, a ZP binding 
molecule, onto the sperm surface (Weerachatyanukul et al., 2003). These results all 
together implicate SGG as an adhesion molecule in sperm maturation and sperm-egg 
interaction.   
Moreover, it has been shown that 70% of SGG in capacitated sperm exists in lipid rafts 
isolated as Triton X-100 resistant membranes, along with cholesterol and saturated 
phospholipids (Bou et al., 2006). Therefore, all these results suggest the roles of SGG 
as a structural lipid contributing to the formation of mammalian sperm lipid rafts, 
which possess ZP-binding molecules needed for the gamete interaction. Isolated sperm 
lipid rafts, in fact, have direct ZP binding ability (Bou et al., 2006). 
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2. PROCESS OF FERTILIZATION 
 
2.1 Fertilization 
 
Fertilization is a complex process of molecular events that involved mature haploid 
male and female gametes and their mutual recognition and fusion to establish the 
genotype of a new individual. Fully matured oocytes and normally differentiated 
haploid spermatozoa are the prerequisites for the success for the fertilization process 
(Kupker et al., 1998). 
A woman is usually fertile on about the 14th day of her menstrual cycle. Days before 
the woman ovulates, her cervix secretes mucus, which allows sperm to travel faster 
towards the uterus and into the fallopian tubes. During ovulation, a mature egg is 
released by the ovary to the fallopian tube and for about 12 to 24 hours, it is ready to be 
fertilized. 
After sexual intercourse the sperm released inside the vagina travel towards the uterus 
to the fallopian tube to seek out the egg. Hundreds of thousands of sperm are released 
during ejaculation, but only one gets to penetrate the egg and starts the fertilization 
process. Sperm are capable of staying alive for 48 to 72 hours inside the female 
reproductive tract, and can fertilize the egg as soon as the ovulation takes place. When 
sperm and egg fuse, a zygote is formed.  
The zygote then undergoes cell division and becomes an embryo. Within five to seven 
days, the embryo is implanted in the uterus. After implantation, the embryo will 
undergo many stages of development, which will be completed within about nine 
months inside the womb.  
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2.2 Male reproductive system 
 
The male reproductive system consists of a set of organs involved in the production of 
sperm. These organs include visible bodies, such as the penis and scrotum, which 
contains the testicles, and internal organs, such as epididymis, seminal vesicles, 
bulbourethral glands and prostate gland (Fig. 3). 
 
 
 
Fig. 3 Male reproductive system 
 
The testicles are involved in the formation of sperm through the process called 
spermatogenesis (Fig. 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Process of spermatogenesis 
 In mammals, spermatogenesis is composed of three phases: the proliferative phase 
during which the diploid spermatogonia undergo several mitotic divisions; the meiotic 
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phase during which primary spermatocytes give rise to secondary spermatocytes which 
themselves divide into haploid spermatids; and the final phase, corresponds to the 
metamorphosis of spermatids into spermatozoa (Alberts et al., 2002; de Kretser and 
Kerr, 1994). 
 
2.3 Spermatozoa: structure and physiology 
 
Highly differentiated and polarized spermatozoa are the final product of the 
spermatogenesis process.  Each spermatozoon consists of two major parts: the head 
which is about  5-10 µm length and the tail which has the length of about 60 µm (Fig. 
5). 
 
 
Fig. 5 Spermatozoa structure 
 
The sperm head consists of a highly compact nucleus, containing the male genome, 
very little cytoplasm and the acrosome.  The acrosome, located on the anterior portion 
of the sperm head, houses hydrolytic enzymes that will aid the spermatozoon to 
penetrate the zona pellucida (ZP), the extracellular glycoprotein matrix surrounding the 
oocyte.  The sperm tail consists of the connecting piece, the midpiece, the principal 
piece, and the end piece.  The connecting piece of the tail is a narrow segment 
containing the paired centrioles.  The midpiece of the tail consists of the helically 
arranged mitochondrial sheath, the axoneme and the outer dense fibers of the 
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flagellum.  The lower limit of midpiece is marked by the termination of the 
mitochondrial helix at the annulus.  The principal piece, the longest segment of the tail, 
is composed of central axoneme surrounded by the outer dense fibers and the fibrous 
sheath.  The end piece is a very short segment of the tail in which only the axoneme is 
present (de Kretser and Kerr, 1994; Eddy and O'Brien, 1994; Kierszenbaum, 2002; 
Yanagimachi, 1994). 
 
2.4 Sperm maturation in male reproductive system 
 
Once formed the spermatozoa begins their journey through the epididymis (Fig. 6). In 
the epididymis, sperm first is transported through the caput and corpus regions and they 
are stored in the proximal cauda epididymis until ejaculation. During epididymal transit 
and storage, sperm acquires its functional competence through a series of 
morphological, biochemical and physiological changes.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 Sperm maturation in epididymis: 1) Caput 2) Corpus 3) Cauda epididymis 
 
Some of the pre-existing proteins on the sperm plasma membrane, such as fertilin alpha 
and beta, cyritestin, alpha-D-mannosidase are cleaved by proteolytic enzymes and 
released into the lumen, or redistributed in different plasma membrane domains 
(Evans, 1999; Gatti et al., 2000). 
A large number of new components, present in the luminal fluid and presumably 
secreted from the epididymal epithelium, are also adsorbed onto the sperm surface 
during the epididymal maturation process (Dacheux et al., 2003).  These new 
components include forward motility protein (FMP) involved in forward motility of 
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sperm (Acott et al., 1983), and proteins with ZP-binding ability, such as P26h (Berube 
et al., 1996), -galactosidase (Sosa et al., 1996; Tulsiani et al., 1995), and arylsulfatase 
A (ASA) (Weerachatyanukul et al., 2001b).  In addition, sperm membrane fluidity 
increases due to the enrichment of polyunsaturated fatty acid (PUFA)-containing 
phospholipids (Cooper and Yeung, 1997; Flesch and Gadella, 2000).  This increased 
membrane fluidity contributes to the sperm capability to move forwardly, as well as to 
the sperm membrane fusion ability required during fertilization (Yanagimachi, 1994).  
Epididymal fluid may also play an important role in sperm maturation; it contains 
membranous vesicles, termed epididymosomes, which interact with sperm (Fornes et 
al., 1995; Frenette and Sullivan, 2001; Yeung et al., 1997).  Proteins and cholesterol 
present in epididymosomes have been shown to be transferred onto the sperm surface 
(Frenette et al., 2002; Saez et al., 2003; Yanagimachi et al., 1985).   
Also in the epididymis, chromatin condensation and stabilization of the spermatozoa 
occur, and the acrosome also acquires its final shape. 
During ejaculation, the spermatozoa are transported from storage in the cauda 
epididymis and are mixed with the prostatic fluid and seminal vesicle fluid before 
passage along the penile urethra. 
The semen ejaculate into the vagina will develop a second set of changes that will take 
place in the female reproductive system. 
  
2.5 Composition and parameter of the human semen 
 
The human semen is composed of two main components: sperm and seminal fluid. A 
grown man, with every ejaculation, emits about 1.5 ml to 6 ml of semen, an amount 
that is dependent on the long passes between one ejaculation to another, by the 
production of testosterone and on individual factors not fully studied. Variable is the 
number of sperm per milliliter of ejaculate, mainly related to the health of the subject; 
this number varies from 20 to 200 million per millilitre. The density of semen depends 
on several factors. In most cases a mass function, but its appearance can vary from a 
creamy eye-catching to a state almost completely liquid, but never transparent.  
The semen of humans contains a complex range of organic and inorganic constituents 
which have protective nourishment for sperm during their journey through the female 
reproductive tract. The vaginal environment is in fact hostile to the sperm cell, it is a 
very acid environment (because of the microflora therein which produces lactic acid), 
 16
viscous and rich in immune cells. Many components present in the semen help in 
compensation with this hostile enviroment to enable sperm to survive long enough to 
reach and fertilize the egg.  
 
2.6 Sperm maturation in the female reproductive system 
 
The female reproductive system consists of a set of organs located in the lower portion 
of the abdomen called pelvi. These organs are mainly internal, such as ovaries, uterus 
and fallopian tube, and they are connected to the outside via the vagina.  
The spermatozoa are deposited in the vagina, near the cervical os, during intercourse. 
Spermatozoa must swim trough the cervical mucus, traverse the uterus, enter the 
oviduct and reach the ampullary portion where fertilization occurs. The sperm motility 
patterns differ, associated with each of these regions, and the spermatozoa are also 
modified during the transport through the female reproductive tract. 
As mention above, the mature sperm are stored in the caudal epididymis until 
ejaculation (Fig. 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7 Sperm maturation in female reproductive tract following the fertilization of the mature egg 
 
The ejaculated sperm then undergo further surface modification in the female 
reproductive tract to gain full fertilizing ability through a process known as 
capacitation.   
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Several processes occur during capacitation: 1) desorption processes during which 
proteins and other macromolecules from epididymal and seminal fluids that mask key 
sites for ZP binding on the sperm surface or suppress sperm functional activity are 
removed; 2) ionic changes in particular those involving in bicarbonate influx and Ca2+ 
influx.  Such changes trigger the activation of adenylyl cyclase, and subsequent 
increase in intracellular cAMP.  As a result, protein kinase A (PKA) is activated, which 
induces downstream protein tyrosine phosphorylation; 3) plasma membrane lipid 
changes. The phospholipids are distributed asymmetrically between the lipid leaflets of 
plasma membrane.  During capacitation, a similar asymmetric distribution occurs in 
sperm and apparently collapses.  The collapse of phospholipid asymmetry facilitates a 
decrease on sperm membrane cholesterol (cholesterol efflux).  The cholesterol efflux 
leads to a decreased ratio of cholesterol to phospholipids and an increase in fluidity of 
the sperm plasma membrane (Cross, 1998).  The global increase in membrane fluidity 
in capacitated sperm is beneficial to the fusion-related events during sperm-egg 
interaction, i.e., acrosome reaction and the sperm-egg plasma membrane fusion 
(Primakoff and Myles, 2002).  However, during the initial interaction between sperm 
and eggs, i.e., sperm-ZP binding, ordered domains on the sperm plasma membrane 
with clusters of ZP-binding molecules would be required for the stable interaction of 
gametes, withstanding the pulling force generated from ongoing sperm movement.  
Recently, results indicate that the levels of liquid-ordered microdomains or lipid rafts, 
which are enriched in cholesterol, saturated phospholipids, and SGG, are increased on 
the sperm plasma membrane following capacitation (Bou et al., 2006; Shadan et al., 
2004).   
This capacitation-related cholesterol efflux is accompanied by activation of lipid 
scramblase (Flesch et al., 2001), which catalyzes the movement of lipids.  This may 
allow sperm lipids to regroup themselves according to their biochemical properties, 
leading to the formation of liquid-ordered microdomains, or lipid rafts.   
Following capacitation, sperm acquire hyperactivated motility patterns and the ZP 
binding sites become exposed, resulting in sperm binding to the egg ZP and subsequent 
penetration through the ZP matrix (Florman and Ducibella, 2006). 
Once the capacitated sperm bind to the ZP, the acrosome reaction is induced.  This 
reaction results in the release of the acrosomal contents, composed mainly of 
hydrolases, which facilitate sperm penetration through the ZP matrix.  Acrosome 
reacted sperm then enter the perivitelline space, bind to and fuse with the egg plasma 
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membrane, and finally one spermatozoon becomes incorporated into the egg proper, 
signifying that fertilization has occurred (Yanagimachi, 1994). 
 
2.7 Sperm interaction to the zona pellucida(ZP) 
 
The binding of sperm to ZP is the first step of gamete interaction, which leads to 
fertilization.  The sperm-ZP binding occurs in two sequential steps, starting with the 
primary binding of the capacitated acrosome-intact sperm to the ZP, followed by the 
secondary ZP binding of the acrosome reacting/reacted sperm (Fig. 8).  
 
 
Fig. 8 Sperm interaction with zona pellucida (ZP) 
 
The ZP consists of a few sulfoglycoproteins, and these glycoproteins are highly 
homologous among species (Wassarman, 2005).  In the mouse, there are three ZP 
matrix glycoproteins: mZP3, mZP2, and mZP1.  During the sperm-ZP binding, mZP3 
serves as the receptor for the primary binding of sperm to ZP, whereas mZP2 is the 
secondary receptor and mZP1 is the cross-linker between mZP2 and mZP3.   
Unlike the ZP, sperm have a number of ZP-binding molecules.  Sperm molecules that 
are involved in the primary ZP binding are localized to the anterior plasma membrane 
of capacitated acrosome-intact sperm head.  Some of these primary ZP binding 
molecules are synthesized in spermatogenic cells and localized to the plasma 
membrane, such as β-1,4-galactosyltransferase (GALT), sulfogalactosylglycerolipid 
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(SGG), mannosidase, and basigin.  Other molecules, such as ASA, P26h, and β-
galactosidase, are synthesized and secreted from the epididymal epithelium into the 
lumen, and adsorbed onto the sperm plasma membrane during the sperm transit trough 
the epididymis (as mentioned in the section of epididymal maturation).  In contrast to 
sperm molecules involved in primary ZP binding, secondary ZP binding molecules, 
such as proacrosin, Sp38, zonadhesin, Sp17 and Sp56 are mostly synthesized in 
spermatogenic cells and they are directly targeted to the acrosome (Tanphaichitr et al., 
2007). 
The reasons for having many ZP-binding molecules on the sperm surface are unknown.  
One possibility that many scientists agree upon is that these molecules may act 
simultaneously/sequentially or serve as a backup for one another during sperm-ZP 
binding, an initial step that crucially leads to the complete fertilization (Tanphaichitr et 
al., 2007). 
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3. AIM OF WORK 
 
Fertilization is the complex process by which haploids gametes, sperm and egg, unite 
to produce a genetically distinct individual. Focusing on the roles of sperm 
sulfogalactosylglycerolipid, it has been shown that SGG participates in sperm zona-
pellucida (ZP)/egg-plasma membrane binding and also is selectively present at 
substantial amount (10 mole% of total lipids) in all mammals (Bou et al., 2006). 
Besides ZP glycoproteins, SGG and its structural analogue sulfogalctosylceramide 
(SGC) have been shown to bind to many other proteins including gp120 of HIV-1 and 
CS6 of enterotoxigenic E. coli. Thus, SGG is considered a site on the sperm with which 
pathogens can interact. 
As SGG plays a key role in the process of fertilization and also in the sexual 
transmitted disease it is believed important to identify a new ligand able to inhibit 
fertilization through the interaction with SGG and, at the same time, having an 
antimicrobial effect. 
In the recent years a new class of cationic antimicrobial peptides (AMPs) has been 
identified. This family of peptide contains species, i.e. cathelicidin, with less than 100 
amino acids, most of which are cationic and hydrophobic, that act as effector molecules 
of the innate immune system, and have a broad spectrum antimicrobial effects on 
Gram-positive and Gram-negative bacteria, and some fungi and enveloped virus. 
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4. ANTIMICROBIAL PEPTIDES 
4.1 The family of antimicrobial peptides 
 
The immune system of multi-cellular organisms comprises a vast arsenal of 
mechanisms to protect the host from constant interactions with infectious 
microorganisms (Boman et al., 2000).  
Antimicrobial peptides (AMPs) are a small cationic peptide which protect their 
hosts against a vast array of microorganism. These peptides are produce by 
several species, including insect, plants and vertebrates, and they are known to 
be evolutionary conserved in several mammalian species (Lehrer et al., 1999). 
The classification of AMPs is difficult owing to their considerable diversity. 
However, based on their amino acid composition, size and conformational 
structures, AMPs can be divided into several categories, such as peptides with 
α-helix structures, (i.e. cathelicidin in human), peptides with β-sheet structures 
stabilized by disulfide bridge, (i.e., defensin in human), peptides with extended 
structures, (i.e., bovine indolicins), and peptides with loop structures, (i.e., 
cyclic defensins found in rhesus macaques (Lai et al., 2009). 
AMPs are expressed on primary barriers of the organism, such as skin, and 
mucosal epithelia, preventing the colonization of host tissues pathogens (Bulet 
et al., 2004). 
Moreover, these peptides are stored in granules within phagocytes, where they 
assist in the killing of engulfed microorganisms (Zasloff et al., 2002; Ganz et 
al., 1999).  
Beside antimicrobial activity, other biological effects of AMPs have been 
describe recently, including neutralization of endotoxins, chemokine-like 
activities, immunomodulating properties, antiviral action, and induction of 
both angiogenesis and wound repair (Yang et al., 2002; Zaiou et al., 2007). 
Due to the board spectrum of their antibiotic properties, AMPs are attractive 
candidates for a novel therapeutic purposes.  
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4.2 Cathelicidins in human: biosynthesis, structure and gene expression 
 
There are several AMPs described in mammals, but we will focus our attention 
on the family of cathelicidins, the most studied AMPs in humans. 
Cathelicidins are synthesized as pre-pro-peptides (Fig. 9) and characterized by 
the conserved amino-terminal sequence of the peptide pro-piece. The carboxy-
terminal domain of the peptide is variable amoung the AMPs, and its possesses 
the antimicrobial activities. The gene for the human cathelicidin is a compact 
gene located in the chromosome 3, and is composed of four exons. Exons 1 to 
3 code for the signal sequence and the cathelin domain, while exon 4 codes for 
the antimicrobial peptide (Larrick et al., 1996; Gudmundsonn et al., 1996). 
 
 
 
Fig. 9 Structure of the gene and peptide of hCAP18/LL37 as a prototypical example for the cathelicidin fami ly. 
The gene is represented schematically with the following individual component: white box, 5’ untranslated region 
(5’UTR); grey box, signal sequence; black box, pro-sequence; shaded box, mature peptide; white box, 3’UTR.  
 
The pro-sequence is termed ‘cathelin’ after the function of this domain to 
inhibit the activity of cathepsin L (cathepsin L inhibitor) and is between 99 and 
114 amino acids long (Zanetti et al., 1996). The ‘cathelin’ protein was initially 
identified from pig leukocytes (Ritonja et al., 1989). Molecules with a 
cathelin-like pro-peptide sequence have been isolated from multiple species 
including cow (Storici et al., 1994), pig (Storici and Zanetti, 1993a and 1993b), 
rabbit (Larrick et al., 1991), sheep (Bagella et al.,1995), human (Agerberth et 
al., 1995; Cowland et al., 1995; Larrick et al., 1995), mouse (Popsueva et al., 
1996; Gallo et al., 1997), monkey (Bals et al., 2001; Zhao et al., 2001) and 
horse (Scocchi et al., 1999) (see more detail in table 2). 
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Table 2 : Amino acids sequence, animal source and structural features of 
cathelicidins from mammals 
 
 
 
The carboxy-terminal domain represents the antimicrobially active peptide that 
varies considerably between individual molecules in sequence, length (12–100 
residues), and function (Table 2). Based on amino acid sequences, mature 
cathelicidin peptides can be organized into three groups: 
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 group I – linear, α-helical peptides without cysteines, i.e. LL37/hCAP-
18 from human 
 group II – peptides with an even number of cysteines linked by disulfide 
bridges, i.e. protegrins (porcine cathelicidin peptides). 
 group III – peptides with an unusually high proportion of one or two 
amino acids, i.e. PR-39 from porcine leukocytes. 
 
Several structural features have been identified as a relevant for the 
microbicidal function of antimicrobial peptide: size, sequence, charge, degree 
of structuring (helicity), overall hydrophobicity, amphipathicity and the angle 
subtended by hydrophobic and hydrophilic surface of the helical molecule 
(Giangaspero et al., 2001). High mean hydrophobicity has been correlated with 
increased cytotoxic activity against eukaryotic membranes (van’t Hof et al., 
2001). 
There is no simple correlation between activity and charge. When the net 
charge becomes more positive, binding to negatively charged surface of 
microorganism is increased (Dathe et al., 1997 and 1999; Wieprecht et al., 
1997). Since all these structural features are strongly interrelated, predicting 
the antimicrobial or cytotoxic activity from a given amino acids sequence is 
difficult. 
In this scenario so it would be interesting to investigate whether this class of 
peptides, which has already been shown for its broad range of action against 
pathogens, can also be used in specific manner in biological processes. For  
these reason we want focusing our attention on hCAP18/LL37, the most 
studied antimicrobial peptide and the only member of cathelicidin family found 
in human.  
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4.3 Human hCAP18 is processed to LL37 or ALL38 (LL37 + Ala N-
terminus) 
 
The human cathelicidin LL37 is generated from the proprotein hCAP18 
encoded by the CAMP gene (Gudmundsson et al., 1996). Following excision of 
the signal peptide, this proprotein is stored in neutrophil granules and 
epithelial cells until activated through cleavage by the serine protease, 
proteinase 3 (Soresen et al, 2001). The actual release of LL37 is proposed to 
occur at the cell surface as, on stimulation of the neutrophil, hCAP18 locates to 
the plasma membrane, potentially through an interaction with an hCAP18 
specific receptors (Stie et al., 2007). In addition to that stored in neutrophils, 
significant quantities of hCAP18 are found in human plasma as complex with 
lipoproteins (Sorensen et al., 2005).  
hCAP18 is also present in the epithelial cells (i.e. in various squamous 
epithelia) (Nilsson et al., 1999), in lungs (Bals et al., 1998; Agerberth et al., 
1999), in sweat glands (Murakami et al., 2002), in salivary glands (Murakami 
et al., 2002), and in keratinocytes during inflammatory disorders (Frohm et al., 
1997). The strongest epithelial expression of hCAP18 is found in the 
epididymis with a subsequent high concentration in seminal plasma (Malm et 
al., 2000; Hammami-Hamza et al., 2001) and is processed by gastricsin to 
generate the antimicrobial peptide ALL38 (LL37 + Ala at the N-terminus) at 
low pH in vagina (Sorensen et al., 2003). 
As suggested by name, LL37 is a 37 residue peptide, positively charged (+6 at 
pH ~ 7.4) (Fig. 10), with high content of hydrophobic aminoacids that adopts 
an α-helical structure in the lipid membranes, micelles, and ions such as 
hydrocarbonate, sulphate and to lesser extent chloride, but is random coil in 
pure water (Nijnik and Hancock, 2009). Finally has been shown previously that 
LL37 has affinity for acidic lipid (Wang, 2008). 
 
 
Fig 10 Structure of LL37 peptide 
Hydrophobic surface 
LL-37     LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES      37 aa  
Hydrophilic surface 
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LL-37 as well as ALL-38 have shown a broad spectrum of activity against both 
Gram-negative and Gram-positive bacteria, various virus, and fungi (Sorensen 
et al., 2003). 
This peptide exhibits potent activity against different bacterial strains, 
including E.coli (Smeianov et al., 2000), Pseudomonas aeruginosa (Travis et 
al., 2000), Klebsiella pneumoniae (Smeianov et al., 2000), Staphylococcus 
aureus, methicillin-resistant S.aureus (Travis et al. 2000), and Neisseria 
gonorrae (Bergman et al., 2005). LL37’s bactericidal activity involves 
membrane disruption (pore formation, change of lipid packing and 
organization) following interaction with negatively charged bacterial 
molecules and insertion into the membrane (Bucki et al., 2010). 
It was also recently proposed that cathelicidins produced by glia and other 
cells may play an important role in the innate immune response against 
pathogens in the central nervous system during bacterial infections 
(Brandenburg et al. 2008). 
A potential antiviral effects of LL-37 is suggested by the finding that treatment 
of human leukocytes with neutralizing antibodies direct against LL37 
significantly reduces the anti-cytomegalovirus (CMV) effect of LTB4, a potent 
mediator of inflammation that possess antiviral activities (Gaudreault and 
Grosselin, 2007). 
HIV-1 replication in peripheral blood mononuclear cells (PBMCs), including 
primary CD4+ T cells, was also compromised in the presence of LL37. This 
inhibition was subsequently reproduced using various HIV-1 isolates without 
detectable changes in the target cells expression of HIV-1 chemokine receptor. 
Accordingly, the HIV-1 inhibitory effect was shown to be independent of 
FPRL-1 signaling. Given the epithelial expression of LL37, this peptide may 
contribute to the local protection against HIV-1 ( Bergman et al., 2007). 
The antimicrobial spectrum of the human cathelicidin LL37 also includes 
fungicidal activity against Candida albican (den Hertog et al., 2006; Lopez-
Garcia et al., 2005). 
All together, these findings indicate a possible application of LL37 peptide in 
the treatment of sexual transmitted disease (STDs). 
Based on the potential characteristics of this peptide reported in the literature, 
we believe that it can be used with a dual purpose. In fact, we believe that 
LL37 can interact with the molecules involved in the process of fertilization 
and especially we aspect that may interact with SGG and mask them to ZP-
binding protein  and also use to prevent by infection from the STDs. 
Processing of hCAP18 to ALL-38 in the ejaculated seminal plasma occurs in 
the vagina by gastricsin, an aspartic enzyme with a pH optimum of 4 (Fig.11).   
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Fig 11 Processing of hCAP18 to LL37 in vagina 
 
However, this processing event takes place 2-6 h post-coitus, the time frame 
needed for the vagina to resume its acidic milieu after the deposition of neutral 
pH seminal plasma. By this time, sperm have already entered the uterine 
cavity; therefore, ALL38 is most likely produced to protect the vagina from 
microbial/viral attacks. In the absence of ALL38-SGG interaction, SGG on the 
sperm surface is free to interact with the ZP. Furthermore, ALL38 and LL37 
have indistinguishable antimicrobial activities (Sorensen et al., 2003).  
For the all reasons listed above, we have considered promising to treat the 
sperm with the exogenous LL37, more easily available, to assess if it could be 
able to block the free SGG on the sperm. Should LL37  inhibit sperm 
fertilizing ability, it  would be a great candidate as a non–hormonal vaginal 
contraceptive with antimicrobial/anti-HIV-1 activity.  
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5. MATERIALS AND METHODS 
 
Lipids  
 
SGG was prepared from pig testis as described previously (Franchini et al., 
2008). Phosphatidylcholine (PC) and phosphatidylserine (PS) were purchased 
from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). Sulfogalactosylceramide 
(SGC) and galactosylceramide (GC) were obtained from Sigma Chemical Co 
(St. Louis, MO).  
 
Proteins 
 
Synthetic antimicrobial peptide LL-37 and the rabbit polyclonal anti LL-37 
antibody was generously given by Dr. Robert E.W. Hancock (University of 
British Columbia, Canada) 
 
Animals  
 
CD-1 male and CF-1 female mice (8- to 12-week-old) were purchased from 
Charles River Canada (St-Constant, QC, Canada). All mice were kept in a 
temperature-controlled room (22 °C) with a 14:10 dark/light cycle. The 
boarding and handling of these mice, as well as all subsequent experimental 
procedures with them, were approved by Animal Care Committee, Ottawa 
Hospital Research Institute (OHRI). 
 
Human sperm sample 
 
With approval from the Human Ethics Committee, Ottawa Health Research 
Institute, Ottawa Hospital Civic Campus the sperm sample were obtained from 
Ottawa Fertility Center (Ottawa, ON, Canada). 
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6. EXPERIMENTAL SECTION 
 
Mouse sperm preparation 
 
The caudal epididymides of CD-1 male were longitudinally scored once with a 
surgical blade and the dense sperm masses squeezed out from this incision and 
from the vas deferens were placed at the bottom of a 1.5 ml microcentrifuge 
tube containing 1ml of KRB-Hepes pre-warmed at 37°C. To prepare Percoll-
gradient centrifuged (PGC) sperm, the sperm suspension was diluted up to 2 ml 
with HEPES-buffered Krebs Ringers bicarbonate (KRB-HEPES) medium 
(KRB-HEPES: 119.4 mM NaCl, 4.8 mM KCl, 1.7 mM CaCl2, 1.2 mM KH2PO4, 
1.2 mM Mg2SO4, 21 mM HEPES,  5 mM NaHCO3, 25 mM sodium lactate, 1 
mM sodium pyruvate, 5.6 mM glucose, 2.8 µM phenol red, pH 7.4), and loaded  
onto a two-step Percoll gradient (45% and 90% Percoll (Amersham 
Biosciences, Uppsala, Sweden) in KRB-HEPES) (Tanphaichitr et al., 1990).  
The gradient  was centrifuged (650 x g, 25°C for 30 min), allowing motile  
sperm to sediment as a pellet and immotile sperm to interface between the two 
Percoll layers. After removing the interfaced  immotile sperm and most of the 
Percoll solution, the pelleted motile sperm were washed once in KRB-HEPES 
(350 x g, 30°C for 10 min), and then were re-suspended and capacitated in the 
Krebs Ringers bicarbonate (KRB) supplemented with 0.3% BSA (KRB-BSA) 
(KRB: 119.4 mM NaCl, 4.8 mM KCl, 1.7 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM 
Mg2SO4, 25 mM NaHCO3, 25 mM sodium lactate, 1 mM sodium pyruvate, 5.6 
mM glucose, 2.8 µM phenol red, pH 7.4) at a concentration of approximately 
10 x 106 sperm/ml (37°C,  5% CO2 for 30 min). An aliquot of appropriately 
diluted (10-20 X) sperm suspension was placed onto a hemocytometer, and the 
numbers of total motile sperm were immediately counted under  a Nikon 
inverted microscope (DIAPHOT-TMD, Nikon Canada, Mississauga,  ON) at 
200 X magnification.  The capacitated sperm were used for in vitro 
fertilization assay (IVF), indirect immunofluorescence (IIF), flow cytometry, 
and immunoblotting after appropriate treatment with different concentrations 
of LL-37 (0.162, 1.62, 3.24, 16.2 and 81 µg/ml). These LL-37 concentrations 
were corresponding to 0.01, 0.1, 0.2, 1, and 5 times molar ratio of SGG amount 
in 1 million sperm, which is 0.36 nmole (Bou et al., 1990). For IVF, after 
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treatment, the capacitated sperm were washed once (350 x g, 30°C for 10 min) 
with KRB-0.3%BSA and re-suspended in the same medium at concentration of 
1 million/ml. For IIF and flow cytometry, the sperm were washed twice with 
PBS containing 0.1% polyvinylpyrrolidone (PVP) and were reconstituted in the 
same buffer. For immunoblotting, the sperm were washed 5 times with PBS-
0.1%PVP and the sperm pellet was used for LL-37 detection by this analysis.   
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Human sperm preparation 
 
With approval from the Human Ethics Committee, Ottawa Health Research 
Institute, Ottawa Hospital Civic Campus, frozen ejaculated semen sample were 
obtained  from frozen sample of fertile donor with normal semen parameter 
(volume 2-6 ml, concentration > 20 x 106 sperm/ml, motility > 50% normal 
morphology > 30%, WHO criteria, 2009). The sperm were washed once in 
Hepes buffered Human Tubal Fluid (HTF) medium (HTF-Hepes: 101 mM 
NaCl, 4.96 mM KCl, 2.04 mM CaCl2, 0.37 mM KH2PO4, 0.2 mM Mg2SO4, 25 
mM NaHCO3, 4 mM sodium lactate, 0.24 mM sodium pyruvate, 2.78 mM 
glucose, 20 mM HEPES, penicillin G 100 U/ml, streptomycin sulfate 50 µg/ml 
and 2.8 µM phenol red, pH 7.4). 
To select motile sperm, sperm were centrifuged through a discontinuous 
Percoll-gradient. The sperm suspension (~0.5 ml) was diluted up to 2 ml with 
Human Tubal Fluid (HTF) medium (HTF: 101 mM NaCl, 4.96 mM KCl, 2.04 
mM CaCl2, 0.37 mM KH2PO4, 0.2 mM Mg2SO4, 25 mM NaHCO3, 21.4 mM 
sodium lactate, 0.24 mM sodium pyruvate, 2.78 mM glucose, penicillin G 100 
U/ml, streptomycin sulfate 50 µg/ml and 2.8 µM phenol red, pH 7.4), and 
loaded onto a two-step Percoll gradient (45% and 90% Percoll (Amersham 
Biosciences, Uppsala, Sweden) in HTF) (Tanphaichitr et al., 1990). The 
gradient  was centrifuged (650 x g, 25°C for 30 min), allowing motile sperm to 
sediment as a pellet and immotile sperm to interface between the two Percoll 
layers. After removing the interfaced immotile sperm and most of the Percoll 
solution, the pelleted motile sperm were washed once in HTF (350 x g, 30°C 
for 10 min), and then were re-suspended and capacitated in the HTF 
supplemented with 0.3% BSA (HTF-0.3%BSA) at a concentration of 
approximately 10 x 106 sperm/ml (37°C,  5% CO2 for 30 min). An aliquot of 
appropriately diluted (10-20 X) sperm suspension was placed onto a 
hemocytometer, and the numbers of total motile sperm were immediately 
counted under a Nikon inverted microscope (DIAPHOT-TMD, Nikon Canada, 
Mississauga,  ON) at 200 X magnification. The capacitated sperm was used for 
immunoblotting after appropriate treatment with different concentrations of 
LL-37 (3.24, 16.2 and 81 µg/ml). The sperm were washed 5 times with PBS 
and the sperm pellet was used for LL-37 detection by this analysis.   
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Mouse In Vitro Fertilization (IVF) 
 
To determine whether LL-37 can inhibit sperm fertilizing ability, IVF was 
carried out as previously described (Tantibhedhyangkul et al., 2002; Wu et al., 
2007). CF-1 females were superovulated by sequential intraperitoneal injection 
of PMSG (5 IU) and hCG (5 IU) (Sigma Chemical Co., St. Louis, MO) with a 
48 h interval.  Ovulated cumulus masses containing mature eggs were retrieved 
from the females 14 h after hCG injection and placed in KRB-Hepes containing 
0.3% BSA. Cumulus layers were dissociated by treating the cumulus masses 
with 0.1% hyaluronidase in KRB-0.3% BSA for 1-2 min (Hogan et al., 1994); 
this freed up the eggs which were then washed with KRB-0.3% BSA and stored 
at 37°C under 5% CO2 until insemination.   
Caudal epididymal and vas deferens sperm of CD-1 male were collected and 
capacitated as describe above. Non-treated and treated capacitated sperm (0.5 
million in 0.5 ml KRB-0.3%BSA) were then co-incubated with approximately 
20 cumulus free eggs in KRB-0.3%BSA under mineral oil for two hours, then 
the eggs were transferred to KSOM containing 0.3%BSA. The KSOM medium 
consisted of 95 mM NaCl, 2.5 mM KCl, 1.7 mM CaCl2, 0.35 mM KH2PO4, 0.2 
mM Mg2SO4, 25 mM NaHCO3, 0.2 mM sodium pyruvate, 10 mM sodium 
lactate, 0.01 mM sodium EDTA, 1 mM L-glutamine, 1 U/ml of penicillin G, 1 
µg/ml of streptomycin sulfate, and 28 µM phenol red at pH 7.4. Six hours 
afterwards, the eggs were scored under an inverted microscope for evidence of 
two-pronuclei formation.  Fertilization rate was defined as percentage of total 
eggs fertilized in each sample. This in vitro fertilization experiment was 
performed in collaboration with Hongbin Xu and Nopparat Srakaew, Ph.D. 
students in Dr. Tanphaichitr’s laboratory. 
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Indirect immunofluorescence and flow cytometry for LL-37 treated mouse  
sperm 
 
Capacitated mouse sperm (treated with different concentrations of LL-37 or 
without the treatment) prepared as described above were incubated in 5% 
normal goat serum (37°C,  30 min), and centrifuged (350 x g, 30°C for 10 min) 
to pellet the sperm. The sperm pellet was re-suspended and incubated with 
affinity purified anti LL-37 polyclonal rabbit  IgG antibody (1:500 dilution in 
PBS) (37°C,  30 min).  The incubation of sperm with this primary antibody was 
omitted for the control group.  After the incubation, the sperm were washed 
twice with PBS and further incubated (37°C,  30 min) with the secondary 
antibody, Alexa-488-conjugated goat anti-rabbit IgG (Molecular Probes) at the 
dilution of 1:200 in PBS.  The sperm were then washed twice with PBS and the 
sperm pellet was re-suspended in 20-50 µl in PBS/glycerol (1:1, v/v). A 8-µl 
aliquot of sperm suspension was mounted onto a slide and topped with a cover 
slip. The slide was viewed under a Olympus fluorescent IX50/IX70 inverted 
system microscope (Olympus America Inc.,  Melville, N.Y, USA). Phase 
contrast and fluorescent images of sperm were recorded by Infinity Capture 
software (Lumenera Corporation, Ottawa, ON, Canada) and processed through 
Image J software (http://rbs.info.nih.gov/ij/).   
The remaining sperm suspension of each treatment was diluted in PBS to 0.5 
ml and subjected to flow cytometric analysis by a Coulter  Epics Profile II Flow 
Cytometer (Beckman Coulter, Fullerton,  CA). Samples were excited by an 
argon ion laser at 488 nm, and the emission fluorescence was monitored at 525 
± 20 nm band pass.  Sperm cells were gated from debris using their unique  
properties of forward and side light scattering.  Data from at  least 10000 events 
were collected, and relative LL-37 staining intensity was determined using FCS 
Express Software (De Novo  Software, Orangeville, ON, Canada). 
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Immunoblotting for LL-37 treated mouse and human sperm 
 
Pellet of capacitated sperm treated with LL-37 as described above was 
solubilized in 1X Laemmli SDS sample buffer (Laemmli, 1970) containing 4M 
urea and 0.2 M DTT (20 µl of this buffer was used for 1 million sperm from 
each treatment). The sperm suspension was sonicated (10 sec for 20 cycle, 
boiled for 5 min and centrifuged (14000 g for 10 min). The supernatant of each 
sample was subjected to 16.5% Gel Tris-Tricine SDS-PAGE (Schägger and 
Von Jagow 1987, Schägger, 2006), followed by electroblotting onto a 
nitrocellulose membrane (Towbin and Gordon, 1984). The nitrocellulose was 
blocked for 1 hour with 5% fat free milk in Tris-buffered saline (TBS: 137 mM 
NaCl in 20 mM Tris-HCl, pH 7.6) containing 0.05% Tween 20.  
Immunoblotting was performed using affinity purified anti-LL-37 polyclonal 
rabbit IgG (1:1000 dilution) as primary antibody, and goat anti-rabbit IgG 
conjugated with horseradish peroxidase (Bio-Rad Laboratories) (1:10000 
dilution) as secondary antibody. The primary and secondary antibodies were 
prepared in the blocking medium. After incubation with each antibody, the 
membrane was washed 5 times (5 min each time) with TBS-0.05% Tween20. 
The reactivity of antibody-antigen was detected by enhanced 
chemiluminescence (ECL) using an ECL kit (Pierce, Rockford, IL).   
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Enzyme linked immunosorbent assay (ELISA) 
 
The binding of LL37 to different types of lipids (SGG, SGC, GC, PS and PC) 
was quantitated using ELISA. Lipids (100 µl in EtOH, containing 1 µg) was 
coated onto a polypropylene 96-well plate (Greiner Bio-one) and dried 
overnight at room temperature (RT) in a dessicator. The plates were then 
blocked with a blocking buffer (TBS at pH 7.4) containing 2% (w/v) BSA and 
0.05% (v/v) TWEEN-20 (100 µl/well) for 1 hour at RT.  After removing the 
blocking solution, 100 µl of protein solution prepared in a TBS buffer 
containing 0.05% (v/v) TWEEN-20 at different concentrations (0, 0.1, 0.25, 
0.5, 0.75, 1.5, 3, 4.5  ng/µl) was added to the wells and incubated with the 
lipids for 1 h.  Following the incubation, the plates were washed three times 
with the washing buffer (TBS at pH 7.4) containing 0.2% (w/v) BSA and 
0.05% (v/v) TWEEN-20 to remove unbound proteins. The primary antibody, 
100 µl of affinity purified anti-LL-37 rabbit polyclonal IgG (1:5000 dilution), 
was added and incubated for 1 h, RT. The plates were washed as above and 
then incubated for 1 h, RT with 100 µl of the secondary antibody goat anti-
rabbit IgG conjugated with horseradish peroxidase (H+L) at 1:3000 dilution 
(Bio-Rad Laboratories). After washing as described above, 100 µl of developer 
solution, containing 0.4 mg/ml of o-Phenylenediamine dihydrochloride (OPD) 
and 0.01% H2O2 in citrate buffer at pH 5.0, was added to each well and 
incubated in the dark until the color was developed.  The quenched solution 
(30% sulphuric acid) was then added and the optical density was determined at 
490 nm. 
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Assessment of acrosome integrity of LL37 treated mouse sperm 
 
To determine whether LL37 binding to the sperm could lead to premature 
acrosome reaction, the acrosomal status of capacitated sperm was assessed 
after LL37 treatment. Capacitated sperm (1 million sperm) prepared as 
described above were treated with different concentrations of LL-37 (1.62, 
3.24 and 16.2 µg/ml in PBS) for 30 min at 37C, 5% CO2. Capacitated sperm 
without treatment and those treated with 10 µM of A23187 were used as 
negative and positive control, respectively. After treatment, the sperm were 
washed twice with PBS and fixed with 4% paraformaldehyde in PBS for 15 
min, RT. Following the fixation, the sperm were washed twice with 0.1 M 
ammonium acetate buffer (pH 9.0) and re-suspended in the same buffer at the 
concentration of 5 million sperm/ml. An aliquot of sperm suspension (10 µl) 
was spreaded onto a 0.25% gelatin-coated glass slide.  The sperm were stained 
with 0.22% Coomassie blue G-250 in 50% methanol, 10% glacial acetic acid.  
The excess dye was removed by washing with distilled water.  Two-hundred 
sperm from each sample were evaluated for their acrosomal status based on the 
Coomassie blue staining patterns using a Zeiss Axioskop light microscope at 
x400 magnification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 37
7. RESULTS 
 
Binding Assay (ELISA test) 
 
LL-37 is a cationic peptide previously shown to bind to acidic lipids, such as  
phosphatidylglycerol (PG), and acidic detergents, such as 
sodiumdodecylsulfate (SDS) (Wang, 2008). Based on this property, LL-37 may 
also bind to SGG and SGC, which are the major sulfoglycolipids in mammalian 
germ cells and myelin sheath, respectively. These anionic lipids may serve as 
receptor for LL37 in the biological process. To first test whether LL37 has 
affinity for SGG and/or SGC, ELISA test was used.  
Using the procedure described in the Material and Methods section we 
obtained the following results: 
 
LL37 
(nM) 
OD SGG OD SGC OD PS 
0 0 0 0 0 0 0 0 0 0 
22.5 0,029 0,008 0,011 0,069 0,046 0,074 0,439 0,421 0,390 
55 0,096 0,124 0,071 0,137 0,133 0,199 0,760 0,699 0,615 
111 0,243 0,226 0,196 0,301 0,305 0,360 1,049 0,942 0,905 
167 0,334 0,326 0,251 0,357 0,360 0,432 1,142 1,331 1,032 
333 0,479 0,503 0,434 0,527 0,494 0,440 1,353 1,315 1,248 
667 0,698 0,764 0,664 0,716 0,648 0,547 1,530 1,487 1,446 
1000 0,705 0,809 0,706 0,702 0,553 0,480 1,497 1,489 1,321 
 
The data were obtained in triplicate 
only for the lipids that showed the 
affinity for the peptide. (SGG, SGC 
and PS)  
 
 
 
 
 
LL37 
(nM) 
OD GC OD PC 
 0 0 0 
22.22 0.017 0.049 
55.55 0.017 0.064 
111.11 0.012 0.081 
166.66 0.006 0.081 
333.33 0.006 0.085 
666.66 0.002 0.096 
1000.00 -0.002 0.096 
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The absorbance value of each sample show above were already subtracted from 
the background values, obtained at 490 nm. All these data were then analyzed 
using graph Pad Prism 5.0. 
 
 ELISA test of SGG/SGC/GC/PS and PC binding to LL37 at pH 7.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACIDIC LIPIDS Kd value (nM) 
Sulfogalactosylceramide (SGC) 157.0 ± 27.8 
Sulfogalactosylglycerolipid (SGG) 455.7 ± 59.1 
Galactosylceramide(GC) n.d. 
Phosphatidylcholine (PC) n.d. 
Phosphatidylserine (PS) 66.7 ± 6.1 
 
Our preliminary data reveled that LL37 indeed has affinity to acidic lipids, and 
in particular for those containing charged structures, i.e., SGC, SGG and PS; 
however, the data suggest that the lipophilic tails of these lipids may also play 
a role in terms of interaction with the peptide. 
In fact, PC, which has a charged structure, and on the other hand, GC, which 
has the same structural features of SGC but it is not charged, do not present 
any affinity for the peptide. 
These data suggest that this peptide most likely presents a specific binding task 
for acid lipids and therefore this it appropriate for our biochemical studies. 
In this context we decided to evaluate the potential role of LL37 in the  
inhibition of sperm fertilizing ability. So we began studies of interaction with 
sperm, probably via SGG, through several techniques like immunoblotting, 
immunofluorescence, flow cytometry and in vitro fertilization. Furthermore we 
intended to look on the ability of LL37 to interfere with the sperm function and 
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for these reason we planned to investigate the integrity of the acrosome 
membrane.  
 
Estimating LL37 concentration for sperm treatment 
 
The LL-37 concentration for sperm treatment was estimated on the basis of the 
amount of SGG on sperm and assuming that SGG is the site for LL37 binding 
to the sperm. One million sperm contain 0.36 nmole of SGG (Bou et al., 2006); 
therefore, 1.62 µg of LL-37 (4.5 kDa) is needed for treatment of one million 
sperm at 1 molar ratio of SGG (1X). Usually, sperm treatment is carried out in 
a 100-µl sperm suspension at a concentration of sperm of 10 million/ml.  In 
this study, different concentrations of LL-37, based on different molar ratios of 
SGG, were used for the sperm treatment (see details in the table below).   
 
 
Concentration of LL-37 (µg/ml) Molar ratios to SGG 
0.162 0.01X 
1.62 0.1X 
3.24 0.2X 
16.2 1X 
81 5X 
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Immunoblotting of capacitated cauda mouse sperm treated with LL37 
 
To investigate whether exogenous LL37 can bind to the sperm in a dose 
dependent manner, the amounts of LL37 on treated sperm were determined by 
immunoblotting.   
Conditions for gel running and 
immunoblotting: 
 
Sample loading; 1 million sperm 
for each treatment 
Gel used and sample preparation 
16.5% polyacrylamide Gel (Tris-
Tricine SDS-PAGE), Samples were 
prepared in a reducing sample 
loading buffer containing, DTT 
and 4M urea and boiled  for 5 
minute prior to use.  
 
 
Primary antibody 
Affinity purified anti-LL-37 polyclonal rabbit IgG (1:5000) 
Secondary antibody 
goat anti-rabbit IgG HRP conjugate (H+L) (1:3000) 
Exposure time 
5 minute 
 
The result obtained showed that exogenous LL37 can bind to the capacitated 
mouse sperm in a dose-dependent manner. We then desidered to investigate the 
site where LL37 binds to sperm, especially on the sperm head where the SGG 
is localized.   
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Indirect immunofluorescence of capacitated mouse sperm treated with 
LL37 
 
Dr. Tanphaichitr group has shown that SGG is present on the anterior head surface 
of the mammalian sperm plasma membrane and is involved in sperm-zona 
pellucida (ZP) binding (White et al., 2002; Weerachatyanukul et al., 2001) 
They have also demonstrated that SGG exists at a substantial amount on the 
sperm surface, namely at 10% mole of the total sperm lipids, and is a main 
component of capacitated sperm lipid rafts, which have affinity for the ZP 
(Bou Khalil et al., 2006). 
Indirect immunofluorescence was used for localization of LL37 on the sperm 
after the treatment. 
 
 
 
 
Untreated sperm 
LL37 treated sperm  (without 1° Ab)  
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After treating sperm with LL37 at the concentration of 0.2X molar ratio of 
SGG, we found that LL37 bound principally on the sperm head surface where 
SGG is localized; however, when the concentration of LL37 was increased to 
1X of SGG molar ratio, staining at the midpiece of sperm was also observed.   
These findings suggest that LL37 may inhibit sperm functions by masking 
SGG on the sperm head surface and it may also bind to other unknown ligands 
on the midpiece and interfere with other sperm functions.   
 
 
 
Sperm treated with 1X LL37  
Sperm treated with 0.2 X LL37  
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Flow cytometry on the capacitated mouse sperm treated with LL37 
 
To confirm the results on the LL37 binding to sperm obtained from indirect 
immunofluorescence, flow cytometry was performed as previously described in 
the Methods section.  
 
 
 
 Line color # Events 
% of gated 
cells 
Geometric 
mean 
Untreated black 38 0.0 8.0 
1° Ab 
(omitted) 
gray 9993 55.0 6.0 
Treated with 
1X LL37 
blue 5463 100.0 1776.0 
 
The high geometric mean obtained from the sperm sample treated with 1X 
concentration of LL37 indicated that all the mouse sperm population analyzed 
showed the binding with the peptide. 
This data not only support the results from indirect fluorescence but also 
confirm that  LL37 at 1X molar ratio of SGG is sufficient for masking all SGG 
molecules present on the sperm head surface.  This concentration of LL37 can 
then be used in the in vitro fertilization experiments to assess sperm fertility.   
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In Vitro Fertilization 
  
To determine whether LL-37 can inhibit sperm fertilizing ability, in vitro 
fertilization (IVF) was carried out as previously described.  
Fertility-related changes on sperm, such as motility and viability, were also 
investigated. After treatment with different concentration of LL37, sperm 
motility and viability were assessed by microscopic analysis and calcein 
fluorescent staining, respectively. This part of experiment was done in 
collaboration with Dr. Hongbin Xu, a former postdoctoral fellow in Dr. 
Tanphaichitr’s laboratory. 
 
 
 
 
 
 
 
 
These results showed that sperm motility and viability were reduced in a 
concentration-dependent manner upon treatment with LL37. Significantly, the 
sperm fertilizing ability was abolished when the sperm were treated with LL37 
at the concentration of 16.2 µg/ml, equivalent to 1X molar ratio of SGG 
amount on sperm. This result suggested that LL37 at this concentration was 
able to completely mask SGG on the sperm head and drastically reduce sperm 
motility and viability.  
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Acrosome Reaction 
 
Another important sperm function that is involved in the sperm fertilizing 
ability is the acrosome reaction, a process resulting in the release of hydrolytic 
enzymes for sperm penetration to the ZP layer prior to fertilize the egg.  In fact 
sperm that undergo acrosome reaction prematurely lost their ability to fertilize 
the egg. 
To investigate whether LL37 can induce premature acrosome reaction, the 
assessment of acrosomal status was carried out as previously described. 
 
 
 
 
The results revealed that LL37 was able to induce premature acrosome reaction 
and when the sperm were treated with  16.2 µg/ml of LL37, 72% of the total 
treated mouse sperm showed  acrosome reacted patterns. 
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8. CONCLUSION 
 
LL37, a broad spectrum antimicrobial peptide (AMP) belonging to the 
cathelicidin family, is a multifunctional host defense peptide that has been 
shown to act against infectious pathogens. The main goal of our study is to 
develop LL37 as a non-hormonal vaginal contraceptive with dual functions.  
These functions include 1) inhibiting the fertilization  by masking the binding 
of SGG present on the sperm head during sperm-egg interaction and 2) 
preventing sexually transmitted infections (STI) by attacking the pathogens. 
The results presented in this thesis strongly support the potential of LL37 as an 
effective non-hormonal vaginal contraceptive with antimicrobial properties.  
Firstly, LL-37 has high affinity for SGG (Kd = 455.7 ± 59.1 ). Secondly, 
exogenous LL-37 binds tightly on  live mouse sperm head, where SGG is 
abundantly expressed, suggesting that LL37 can inhibit sperm function by 
interaction with SGG. Thirdly, the binding of exogenous LL-37 to sperm 
decreases the sperm motility and viability.  The reduction of sperm motility 
may be related to the observed additional binding of LL37 to the midpiece 
region where mitochondria are localized.  Treatment of sperm with 1X molar 
ratio of LL-37 to SGG completely abolishes the sperm’s fertilizing ability.  
The impairment in sperm functions is likely due to premature acrosome 
reaction induced by LL-37 treatment, given that 72% of sperm undergo 
acrosome reaction after treating with 1X molar ratio of LL-37 to SGG. 
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9. FUTURE AND PROSPECTIVE 
 
Based on the effects of LL37 on the mouse sperm fertilizing ability, we would 
like to expand our study to investigate the role of LL37 on human sperm.   
Preliminary results shown here were obtained from treatment of  frozen 
capacitated human sperm with exogenous LL37 following by immunoblotting 
analysis. 
The experiment was carried out as precendently described. 
 
 
 
The result shown a specific protein band around 18-kDa correlated to hCAP18 
and other two protein band at 4-kDa and 8-kDa corresponding to the monomer 
and dimer of LL37. Furthermore these data suggest a specific binding of 
exogenous LL37 in a dose-dependent manner to the human sperm. 
These preliminary results prompt us to further investigate the effects of LL37 
on human sperm fertilizing ability, which will fulfill our goal in developing 
LL37 as a non hormonal contraceptive.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conditions for running gel and immunoblotting: 
Sample loading 1 million sperm for each 
treatment 
Gel used and sample preparation; 
16.5% polyacrylammide Gel (Tris-Tricine 
SDS-PAGE), sample were prepared in 
reducing sample loading buffer containing, 
DTT and 4M urea and boiled  for 5 
minutes prior to use 
Primary antibody 
Affinity purified anti-LL-37 polyclonal 
rabbit IgG 1: 1,000 
Secondary antibody 
Goat anti-rabbit IgG HRP 1: 10,000 
Exposure time 4 minute 
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SECTION II 
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10. INTRODUCTION 
 
 
Sponges (Porifera) are metazoans that have developed for 600 million years, and today 
are found in many different marine habitats and also in freshwater lakes and streams 
(Brusca and Brusca, 1990). It is well know that marine sponges are a rich source of 
bioactive compounds that play an important role of protection against predator, 
overgrowing space competitor and invading microorganisms (Pawlik et al., 1993). 
Over the past three decades, several biologically secondary metabolities have been 
isolated from marine sponges and used as new therapeutic agents (Towle et al., 2001). 
More recently, it has been shown that some metabolites in sponges are actually 
biosynthesized by microorganisms, mostly bacteria, living as a symbionts in the sponge 
(Piel et al., 2004). This is not surprising, if one considers that in some species, such as 
Plakortis Simplex, bacterial symbionts constitute 50% of the mass of the organism, an 
there are 80 times more bacterial cells than sponge cells (Laroche et al., 2007). 
Sponges of the genera Agelas and Axinella were shown to contain a unique class of 
glycosphingolipids with an α-galactose as the first sugar of the saccharide chain 
(Costantino et al., 1995). Such glycolipids are immunostimulating if the OH group at 
position 2 of the inner galactose is not glycosylated (Costantino et al. 1996). Due to 
their immunostimulating activity, agelasphins (α-galactosylceramides) and their 
synthetic analogue KRN-7000 (Kobayashi, 1995) (Fig. 12) show a remarkable in vivo 
antitumor activity (Motoki et al., 1995);  the latter compound is being currently tested 
as a candidate anti-cancer drug. 
 
 
 
Fig. 12 KRN7000 structure 
 
More recently, it has been shown that other two molecule, plakoside A (Fig. 13 (a)) and 
B (Fig. 13 (b)) two prenylated glycosphingolipids, show potent immunosuppressive 
properties. 
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Fig.13 Plakoside structure 
 
These unique glycolipids were isolated from the Caribbean sponge Plakortis simplex.  
In the context of molecule that exhibits immunomodulating activities we will focuse 
our attention on a new class of atypical glycolipids, i.e simplexide, which is product 
from a symbionts bacteria present in the Plakortis Simplex sponge, and had been shown 
as a potent  stimulator for the production of unique profile of cytokine from human 
peripheral blood mononuclear cells (PBMC) (Loffredo et al., 2010 in press). 
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11. SIMPLEXIDE 
                                
Simplexide is a unique glycolipid which is found in the sponge Plakortis Simplex (Fig. 
14), but is produced by the bacterial simbionts of the sponge. 
 
 
 
Fig. 14 Caribbean sponge Plakortis Simplex 
 
It is a diglycosylated very long chain secondary alcohol, with the OH group at about 
the middle of alkyl chain. The OH group is glycosylated by  a β-galactopyranose, 
which in turn is glycosylated at position 4 by an α-glucopyranose. 
Glycosylated long-chain secondary alcohols have never been reported as natural 
compounds, so that simplexide can be considered the first member of a new class of 
glycolipids (Fig. 15). 
 
 
 
Fig. 15 Simplexide structure 
 
Another unusual feature of simplexide is the very long chains of the lipid part, which 
presents heterogenicity and is composed of 34-37 carbon atoms with the hydroxyl 
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group nearly in the middle, although the species more represented is the one with 35 
carbon atoms. 
This suggests that the lipid part of simplexides could be biosynthesized from the 
coupling of two molecules of fatty acid. A reasonable biogenetic hypothesis is sketched 
in Scheme 1.  
 
At the time of its first isolation, simplexide had shown immunosuppressive activity in a 
preliminary assay on a pure population of murine T cells. Micromolar concentration of 
simplexide were able to inhibit concanavalin-A induced proliferation of lymph-node 
cells (Ianaro et al., 1995). The activity of simplexide has been recently tested 
measuring the effect on cytokine and chemokine production from PBMC (Fig. 16) 
(Loffredo et al., 2010 in press). 
 
Fig. 16 Activities of simplexide on PBMC 
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The result of these experiments were particularly interesting, because the simplexide 
turned out to be a potent stimulus for the production of IL-6, IL-8 and IL-10 from 
human PBMC. In contrast, simplexide has no effect on TNF-α release. The cytokine 
profile induced by simplexide appears quite unique, because classic activation of 
PBMC (i.e. by LPS or immunocomplexes) always result in the production of TNF-α 
(Loffredo, 2010 in press). 
Interestingly, simplexide is very potent in stimulating human PBMC, and the highest 
concentration tested (10 µM) its effect on the synthesis of IL-6 and IL-8 is comparable 
to that of LPS, the most potent stimulus know for human PBMC activation. 
Preliminary investigation to identify the receptor activated by simplexide showed the 
Toll-like receptor-2 and 4 (TRL-2 and 4), the receptors engaged by LPS, are not 
involved in the effect of simplexide (Fig.17). 
 
 
Fig. 17 Binding receptor 
 
Among the possible receptors for  simplexide, it has been considered CD1d, a protein 
expressed on the surface of antigen presenting cell (APC), which can bind lipid or 
glycolipid antigens and activate cytokine release from monocytes and NK cells (Exley 
et al., 2000). The anti-CD1d antibody induced a cytokine profile which is quite similar 
to that induced by simplexide (IL-6, IL-8, IL-10 but not TNF-α). The data shown 
suggest that the effects of simplexide may be mediated by CD1d. This hypothesis is 
further supported by the observation that α-GalCer, the reference ligand for CD1d ( 
Koch et al., 2005), is capable for inducing a cytokine profile similar to that simplexide, 
although at a 100-fold higher concentration.   
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Overall, these results show that simplexide is a potent inducer of a unique cytokine and 
chemokine profile and its able to modulate lymphocyte and monocyte functions. 
Therefore, it is conceivable that simplexide may have immunoregulatory properties 
that may be potentially  useful for treatment of neoplastic and autoimmune disease. 
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12. AIM OF WORK 
 
Simplexide, a long chain secondary alcohol glycosylated by a disaccharide (Fig. 18) is 
a glycolipid isolated from the marine Caribbean sponge Plakortis Simplex (Costantino 
et al., 1999).  
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Fig. 18 
 
Simplexide shows immunosuppressive activity and strongly inhibits proliferation of 
activated T cells without cytotoxic activity (Costantino et al., 1999). More recently, a 
very interesting and unique pattern of cytokines release from PBMC (Peripheral Blood 
Mononuclear Cells) was observed after stimulation with simplexide (Loffredo et al., 
2010 in press). This unprecedented profile makes simplexide a potential lead for the 
treatment of autoimmune diseases. Nevertheless, more detailed studies are needed in 
order to understand the biochemical mechanism of action and for a better 
comprehension of the structural requirements for activity. 
In this context a synthetic approach towards the preparation of a simplexide fluorescent 
probe (Hoang et al., 2003; Im et al., 2004) has been developed. This compound will be 
functional to evaluate the subcellular distribution of the glycolipid and to clarify its 
mechanism of action.In particular, the analogue (1) (Fig.19), with a fluorescent group 
(i.e dansyl), attached to the position 6 of glucose through a spacer arm, has been 
designed and prepared during my Ph.D period. 
 
 
Fig. 19 Fluorescent analogue of simplexide 
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In order to minimize inaccurate results it is important that the addition of the 
fluorescent probe does not interfere in the association of the ligand with its host. The 
choice of position 6 of glucose should meet these requirements, since preliminary 
results revealed that the biological receptor of simplexide should be the CD1d protein, 
which recognizes glycolipids by docking their lipid part in the hydrophobic binding 
region while leaving the polar head group protruding from the surface of the protein 
binding groove for T cell recognition (Koch et al., 2005; Borg et al., 2007). 
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13. RESULTS 
 
13.1 Synthetic approach 
 
We have designed a retrosynthetic strategy (Fig. 20) and planned to obtain fluorescent 
simplexide (1) through glycosylation between the preformed activated disaccharide 
(14) (LG = leaving group) and the lipid moiety. In turn disaccharide could be obtained 
through glycosylation  between a glucosyl donor (9) selectively functionalized with an 
azido group at position 6 and galactoside (13). The hydroxyl protecting group in both 
saccharides have been chosen in order to guarantee the correct stereochemistry in the 
formation of the glycosydic bonds. The lipid acceptor is commercial available.  
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Fig 20 Retrosynthetic scheme of fluorescent simplexide 
 
Following this retrosynthetic scheme we have planned the synthesis of the single sugar 
moiety necessary to obtain the fluorescent simplexide. 
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13.2 Synthesis of glucosyl donor 
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Scheme 2. a. Allyl alcohol, BF3Et2O, DCM, RT, 3 h (60%). b. MeONa, MeOH, RT, overnight (99%). 
c. Tosyl chloride, Py, 0 °C, overnight (80%). d. Sodium azide, TBAI, DMF, 80 °C, 6 h (90%). e. Benzyl 
bromide, NaH, DMF, 55 °C, 1,30 h (90%). f. Ir catalyst, THF, then NBS, H2O, 3 h (70%). g. Cl3CCN, 
K2CO3, DCM, RT, 20 h (77%). 
 
The synthesis of the glucosyl donor was performed as described above. 
Compound (3) was obtained by reaction of commerciable available β-D-glucose 
pentaacetate with allyl alcohol in dichloromethane and boron trifluoride di-ethyl 
etherate as the catalyst (yield 60%). Then, the protecting groups were removed in a 
quantitative yield by methanolysis and the product (4) was used without purification 
and functionalized in position 6 through reaction with tosyl chloride in pyridine to give 
compound (5) (yield 80%). 
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The tosyl group was subsequently replaced with an azido functionality in order to 
obtain compound (6) by reaction with sodium azide in DMF catalyzed by tert-butyl 
ammonium iodide (yield 90%) . 
Compound (7) was obtained by reaction of the hydroxyl group of compound (6) with 
sodium hydride in N,N-dimethylformamide and subsequent treatment with benzyl 
bromide (90%). Finally compound (9) was achieved via the intermediate (8) by 
treatment with trichloroacetonitrile and potassium carbonate in dichloromethane (yield 
77%). 
Compound (9) was then used for the glycosylation with galactosyl acceptor. 
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13.3 Synthesis of galactosyl acceptor 
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Scheme 3. a. Allyl alcohol, BF3Et2O, DCM, RT, 3 h (70%). b. MeONa, MeOH, RT, overnight (99%). 
c. Benzoyl chloride, Py, -30 °C, 1 h (50%).  
 
The synthesis of the galactosyl acceptor (13) was performed as described above. 
Compound (11) was obtained for reaction of commercial available β-D-galactose 
pentaacetate (10) with allyl alcohol in dichloromethane and boron trifluoride di-ethyl 
etherate as the catalyst (yield 70%). Then, the protecting groups were removed in a 
quantitative yield by methanolysis and the product (12) was used without purification 
to obtain the compound (13) by selectively benzoylation through reaction with benzoyl 
chloride in pyridine at low temperature (yield 50%). 
Compound (13) was used for the glycosylation with the glucosyl donor. 
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13.4 Synthesis of fluorescent simplexide 
 
OBnO
BnO
BnO
N3
O
O
BzO
BzO
O
OBz
OBnO
BnO
BnO
N3
O
O
BzO
BzO
OH
OBz
OBnO
BnO
BnO
N3
O
O
BzO
BzO
OBz
O
NH
CCl3
OBnO
BnO
BnO
N3
O
O
BzO
BzO
OBz
O
C16H33
C16H33
OHO
HO
OH
NH
O
O
HO
OH
OH
O
C16H33
C16H33
SO
O
N
O
HO
BzO
BzO
OBz
O
O
BnO
BnO
BnO
O
N3
NH
CCl3
(9)
(13)
(14)
(15)(16)
(17) (1)
a
b
c
d
 
 
Scheme 4. a TMSOTf, Et2O dry, MS 4 Å, -40 °C, 0.5 h (53%). b. Ir catalyst, THF, then NBS, H2O, 3 
h (71%). c. Cl3CCN, DBU, DCM, RT, 20 h (80%). d. 18 pentatria-contanol, MS AW300, CHCl3 dry, 0 
°C, 0.5 h, then TMSOTf, RT, 0.5 h (83%). 
 
The synthesis of fluorescent simplexide was achivied by the scheme describe above. 
Compound (14) was obtained through glycosylation between the glucosyl donor (9) 
and galactosyl acceptor (13) catalyzed with trimethylsilyl trifluoromethansulfonate in 
dichloromethane (yield 53%). Then, compound (16) was achieved by initial formation 
of intermediate (15), obtained through deprotection of the anomeric position  of 
compound (14), followed by treatment with trichloroacetonitrile and 1,8-
diazabiciclo[5.4.0]undec-ene in dichloromethane (yield 80%). Finally compound (17) 
was obtained by pretreatment of a solution of compound (16) and  long chain alcohol, 
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18-pentatria-contanol, in dry chloroform with acidic MS AW300, followed by 
treatment with a solution of trimethylsilyl trifluoromethansulfonate (yield 83%). 
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14. EXPERIMENTAL SECTION 
 
 
 General Methods 
 
 Optical rotations were determined on a Perkin-Elmer 241 polarimeter at 20°C.  
 All NMR spectra were recorded at 298 K with a Bruker FT-NMR Avance 
DRX500 spectrometer in CDCl3 or CD3OD solutions with TMS as internal 
standard.  
 The mass spectrometric analyses were performed in electron impact (EI-MS) 
ionization at an electron energy of 70 eV with a source temperature of 250°C 
and in negative or positive electrospray (ESI-MS). MS spectra were recorded 
on a Hewlett-Packard HP-5988-A or a Thermo Quest Finnigan LCQ™deca ion 
trap mass spectrometer; the mass spectrometer was equipped with a Finnigan 
ESI interface; data were processed by Finnigan Xcalibur software system. 
 All reactions were monitored by TLC on Silica Gel 60 F-254 plates (Merck) 
with detection by spraying with 50% H2SO4 in MeOH/H2O (1/1) solution or 
with phosphomolybdate-based reagent and heating to 110 °C. Flash column 
chromatography was performed on Silica Gel 60 (230-400 mesh, Merck).  
 Dry solvents and liquid reagents were distilled prior to use: THF was distilled 
from sodium; dichloromethane and pyridine were distilled from calcium 
hydride; DMF, methanol were dried on 4 Å molecular sieves; CHCl3 was put 
under stirring on calcium chloride, then was filtred and trhough on allumina 
column (neutr., Typ 507C, 150 mesh, Sigma-Aldrich) and finally were dried on 
4 Å molecular sieves. 
 All reagents were purchased from Sigma-Aldrich. 
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Synthesis of Allyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside (3) 
 
 
O
AcO
AcO
AcO
OAc
OAc
O
AcO
AcO
AcO
O
OAc
1)Allyl  alcohol
2)BF3Et2O
DCM dry; RT; 3 h
(2) (3)
 
Compound P(g) V(ml) d(g/ml) M.W. mmol Eq 
(2) 6   390.27 15.37 1 
Allyl alcohol  2.51 0.852 58.08 36.90 2.4 
BF3Et2O  5.79 1.13 141.93 46.11 3 
CH2Cl2 dry  39     
Theoretical (3) 5.96   388.1 15.37  
 
Boron trifluoride di-ethyl etherate (5.79 ml, 46.11 mmol) was added dropwise to a 
solution of compound (2) (6 g, 15.37 mmol) and allyl alcohol in dry dichloromethane 
at 0 °C. The ice bath was removed after 0.5 h, and the reaction was allowed to warm to 
room temperature and kept under stirring until the starting material had been consumed 
(monitored by TLC). The reaction mixture was quenched with a aqueous saturated 
sodium bicarbonate solution (200 ml), then was extracted with dichloromethane (3*50 
ml). The organic layers were washed with Brine(2*100 ml), drying (Na2SO4) and 
evaporated under vacuum. The crude residue was chromatographed on silica column 
with ethyl acetate/petroleum ether 4/6 to afford 3.57 g of compound (3). Yield: 60%. 
 
TLC AcOEt/ETP 5/5 Rf (3) = 0.52 
 
(3)
(2)
(2) X R  
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Allyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside (3) 
 
 
 
(3)
O
AcO
AcO
AcO
O
OAc
 
 
 
 Amorphous solid 
 Mol. Wt. = 388.4 
 Exact mass = 388.1 
 C17H24O10 
 This product has been characterised by comparison of its physical data ( [α]D, 
1H NMR, 13C NMR) with that reported (Kishida et al., 2005). 
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Synthesis of Allyl-β-D-glucopyranoside (4) 
 
O
HO
HO
OH
O
OH
1)MeONa
MeOH dry,
0 °C to RT, overnight
(4)
O
AcO
AcO
AcO
O
OAc
(3)
 
Compound P(g) V(ml) d(g/ml) M.W. mmol Eq 
(3) 3.57   388.1 9.19 1 
Sol. MeONa 1 M  18.38    18.38 2 
MeOH dry  16.0     
Theoretical (4) 2.02   220 9.19  
 
An ice-cold solution of compound (3) (3.57 g, 9.19 mmol) in dry MeOH (16 ml) was 
treated with a freshly prepared  solution of sodium methoxide in methanol (18.3 ml sol 
1M). The ice bath was removed after 0.5 h, and the reaction was allowed to warm to 
room temperature and stirred overnight. The reaction mixture was quenched with an 
ion exchange resin (Dowex Marathon C - H+ form activated). The resin was filtered off 
and the filtrate was concentrated under vacuum to obtain 2.01 g of compound (4), 
Yield 99%.   Compound (4) was used in the next step without further purification. 
 
TLC AcOEt/ETP 5/5 Rf (4) = 0                   TLC AcOEt/MeOH 9/1 Rf (4) = 0.25 
(3)
(4)
(3) RX (3) RX
(3)
(4)
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Allyl-β-D-glucopyranoside (4) 
 
 
(4)
O
HO
HO
OH
O
OH
 
 
 Amorphous solid 
 Mol. Wt. = 220.2 
 Exact mass = 220.1 
 C9H16O6 
 This product has been characterised by comparison of its physical data ( [α]D, 
1H NMR, 13C NMR) with that reported in (Kishida et al., 2005). 
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Synthesis of Allyl 6-O-tosyl-β-D-glucopyranoside (5) 
 
O
HO
HO
OH
O
OTs
1)Tosyl  chloride
Py dry; 0 °C, 
overnight
(4) (5)
O
HO
HO
OH
O
OH
 
Compound P(g) V(ml) d(g/ml) M.W. mmol Eq 
(4) 1,96   220 8.91 1 
Tosyl chloride 2,89   190.65 15.15 1.7 
Pyridine dry  61     
Theoretical (5) 3.33   374.1 8.91  
 
 
To a solution of compound (4) (1,96 g, 8.91 mmol) in dry pyridine (61 ml) was added 
4-toluensulfonyl chloride (2.89 g, 15.15 mmol) at 0 °C. The reaction was stirred at 0 °C 
overnight. The reaction mixture was quenched with MeOH and pyridine was remove 
under vacuum. The residue was purified by chromatography  with ethyl 
acetate/methanol 9/1 to afford 2,66 g of compound (5). Yield: 80%. 
 
TLC AcOEt/MeOH 9/1 Rf (5) = 0.60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
(5)
(4)
(4) RX
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Allyl-6-O-tosyl-β-D-glucopyranoside (5) 
 
 
 
O
HO
HO
OH
O
OTs
(5)
 
 
 
 Amorphous solid 
 Mol. Wt. = 374.4 
 Exact mass = 374.1 
 C16H22O8S 
 1H NMR (500MHz, CDCl3):  = 2.47 (s, 3 H, CH3), 3.16 (dd, 1 H, J1,2 = 8.1, J2,3 
= 9.2 Hz, H-2), 3.22 (t, 1 H, J3,4 = J4,5 = 9.2 Hz, H-4), 3.31 (t, 1 H, J2,3 = J3,4 = 
9.2 Hz, H-3), 3.39 – 3.45 (m, 1 H, H-5), 4.01 – 4.10 (m, 1 H, 
OCHaHbCH=CH2), 4,17 (dd, 1 H, J5,6a = 6.1 Hz, J6a,6b = 10.8 Hz, H-6a), 4.18-
4.28 (m, 2 H, H-1 and OCHaHbCH=CH2), 4.36 (dd, 1 H, J5,6a = 1.7 Hz, J6a,6b = 
10.8 Hz, H-6b), 5.14-5.21 (m, 1 H, CH=CHaHb), 5.30-5.36 (m, 1 H, 
CH=CHaHb), 5.88-5.99 (m, 1 H, CH=CH2), 7.42 -7. 50 (m, 2 H, arom), 7.79 -
7.85 (m, 2 H, arom) ppm. 
 13C NMR (CD3OD):  = 20.2, 69.4, 69.7, 69.8, 73.4, 73.6, 76.5, 101.9, 116.2, 
127.7 (2 C), 129.6 (2 C), 133.0, 134.4, 145.1 ppm. 
  []D20 = - 21,0 (c = 1 in methanol) 
 ESI-MS (positive-ion mode) : m/z =397.1 (100) [M + Na]+, 770.7 (40) [2M 
+ Na]+ 
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Synthesis of Allyl 6-Azido-6-deoxy-β-D-glucopyranoside (6) 
 
O
HO
HO
OH
O
N3
2)TBAI
DMF dry, 80 °C, 
6 h
(5) (6)
O
HO
HO
OH
O
OTs
1)Sodium azide
 
Compound P(g) V(ml) d(g/ml) M.W. mmol Eq 
(5) 2.66   374 7,11 1 
Sodium azide 1,38   65,01 21.33 3 
TBAI 0,52   369,37 0,14 0,02 
DMF dry  50     
Theoretical (6) 1.74   245.2 7.11  
 
 
A mixture of compound (5) (2.66 g, 7.11 mmol), sodium azide (1.38 g, 21.33 mmol) 
and a catalytic amount of tetra-n-butyl-ammonium iodide (0.52 g, 0.14 mmol) in dry 
DMF (50 ml) was put under stirring at 80 °C. After the reaction was complete (6 h 
approx.), DMF was removed under high vacuum and the residue was purified through 
flash column chromatography with dichloromethane/methanol 9/1 to afford 1,57 g of 
compound (6). Yield: 90%. 
 
TLC CH2Cl2/MeOH 9/1 Rf (6) = 0.26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(6)
(5)
(5) RX
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Allyl-6-Azido-6-deoxy-β-D-glucopyranoside (6) 
 
 
 
O
HO
HO
OH
O
N3
(6)
 
 
 
 Amorphous solid 
 Mol. Wt. = 245.2 
 Exact mass = 245.2 
 C9H15O5N3 
 1H NMR (500MHz, CD3OD) : δ = 3.19-3.54 (m, 6 H, H-2, H-3, H-4, H-5 and 2 
H-6), 4.14–4.21 (m, 1 H, OCHaHbCH=CH2), 4.31-4.39 (m, 2 H, H-1 and 
OCHaHbCH=CH2), 5.16-5.23 (m, 1 H, CH=CHaHb), 5.30-5.38 (m, 1 H, 
CH=CHaHb), 5.92-6.01 (m, 1 H, CH=CH2) ppm. 
 13C NMR (CD3OD):  = 51.4, 69.7, 71.2, 73.7, 75.7, 76.5, 101.9, 116.2, 134.2 
ppm. 
 []D20 = - 81.5 (c = 1 in methanol) 
 ESI-MS (negative-ion mode) : m/z = 243.9 (30) [M - 1]-, 498.0 (100) [2M - 
1]- 
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Synthesis of Allyl 6-azido-6-deoxy-2,3,4-tri-O-benzyl-β-D-
glucopyranoside (7) 
 
O
BnO
BnO
BnO
O
N3
2)BnBr, rt
DMF dry, 55 °C, 
6 h
(6) (7)
O
HO
HO
OH
O
N3
1)NaH, 0 °C
 
Compound P(g) V(ml) d(g/ml) M.W. mmol Eq 
(6) 1,5   245 6,12 1 
NaH 60% 1,64   23 42,8 7 
BnBr 9,42 6,55 1,44 171,04 55,08 9 
DMF dry  50     
Theoretical (7) 3.15   515.2 6.12  
 
Sodium hydride (60% in mineral oil, 1,64 g, 42.8 mmol, previously washed three times 
with n-hexane)  was added under anhydrous condition at 0 °C to a solution of 
compound (6) (1.5 g, 6.12 mmol) in dry DMF (50 ml), and the foaming gray reaction 
was then allowed to warm to room temperature. Benzyl bromide (6.55 ml, 55.08 
mmol) was slowly added, and the slurry was then heated at 55 °C and vigorously 
stirred at this temperature for 6 h. After MeOH had been added to destroy the excess of 
NaH, the mixture was concentrated under high vacuum, and then diluted with ethyl 
acetate (100 ml)  and washed with water (200 ml). The aqueous layer was further 
extracted with ethyl acetate (2* 50 ml). The combined organic extract were dried 
(Na2SO4) and concentrated. The residue was purified on flash column chromatography 
with petroleum ether/ethyl acetate 9/1 to afford 2.84 g of compound (7). Yield: 90%. 
TLC ETP/AcOEt 9/1 Rf (7) = 0.32 
 
 
 
 
 
 
 
 
 
 
 
(7)
(6)
(6) RX
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Allyl 6-azido-6-deoxy-2,3,4-tri-O-benzyl-β-D-glucopyranoside (7) 
 
 
 
O
BnO
BnO
BnO
O
N3
(7)  
 
 
 Amorphous solid 
 Mol. Wt. = 515.6 
 Exact mass = 515.2 
 C30H33O5N3 
 1H NMR (500MHz, CDCl3) : δ = 3.31-3.73 (m, 6H, H-2, H-3, H-4, H-5 and 2H-
6), 4.16 – 4.21 (m, 1 H; OCHaHbCH=CH2), 4.43 - 4.48 (m, 1 H, 
OCHaHbCH=CH2), 4.52 (d, 1 H, J1,2 = 7.81 Hz, H-1), 4.56 – 5.03 (3 d, 6 H, J = 
10.8 Hz, CH2Ph) 5.22-5.28 (m, 1 H, CH=CHaHb), 5.35-5.41 (m, 1 H, 
CH=CHaHb), 5.93-6.03 (m, 1 H, CH=CH2), 7.24-7,41 (m, 15 H arom.) ppm. 
 13C NMR (CDCl3):  = 51.5, 70.3, 74.7, 74.9, 75.0, 75.7, 78.4, 82.3, 84.5, 
102.5, 117.6, 127.7-128.5 (15 C), 133.8, 137.7, 138.3, 138.4 ppm. 
 []D20 = + 7,1 (c = 1 in chloroform) 
 ESI-MS (positive-ion mode) : m/z = 538,1 (100) [M + Na]+ 
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Synthesis of 6-azido-6-deoxy-2,3,4 tri-O-benzyl-β-D-glucopyranoside 
(8) 
 
O
BnO
BnO
BnO
O
N3
THF dry, RT, 3 h
(7)
O
BnO
BnO
BnO
OH
N3
(8)
1)NBS
2)THF, H2O
RT, 30 min
Ir(C9H12)[PMePh2]2PF6
1° step
2° step
 
Compound P(g) V(ml) d(g/ml) M.W. mmol Eq 
(7) 1   515 1.94 1 
Ir(C9H12)[PMePh2]2PF6 0.05 
10.8 di 
THF 
dry 
 845.79 0.058 0.03 
THF dry  23.5     
NBS 0.52   177.99 2.91 1.5 
H2O  6.5     
THF  100     
Theoretical (8) 0.92   475 1.94  
 
To a solution of compound (7) (1 g, 1,94 mmol)  in THF dry (23.5 ml) was added 
dropwise a solution of Ir catalyst (49 mg, 0.058 mmol in 10.8 ml THF dry), previously 
activated with  hydrogen for 0.5 h, under anhydrous condition at RT, then the reaction 
mixture was stirred for 3 h at RT. After this time NBS (0.52 g, 2.91 mmol), water 
(6.5ml) and THF (100 ml) were added and the reaction mixture was stirred for 0.5 h, 
then the THF was removed under vacuum.  The residue was diluted with ethyl acetate, 
washed with a aqueous saturated sodium bicarbonate solution (200 ml) and Brine 
(2*100 ml). Drying (Na2SO4) and evaporation of the ethyl acetate layer gave a crude 
residue that was chromatographed on silica column with ethyl acetate/petroleum ether 
4/6 to afford 0.64 g of compound (8). Yield: 70%. The 
identity of the compound was assessed through MS 
experiment. Compound (8) was used in the next step 
without further characterization. 
 
TLC ETP/AcOEt 8/2 Rf (8) = 0.32 
 
 
(8)
(7)
(7) RX
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6-azido-6-deoxy-2,3,4 tri-O-benzyl-β-D-glucopyranoside (8) 
 
 
 
O
BnO
BnO
BnO
OH
N3
(8)  
 
 Amorphous solid 
 Mol. Wt. = 475.5 
 Exact mass = 475.2 
 C27H29O5N3 
 ESI-MS (positive-ion mode) : m/z = 498.2 (100) [M + Na]+, 972.8 (33) [2M 
+ Na]+ 
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Synthesis of 6-azido-6-deoxy-2,3,4-tri-O-benzyl β-D-glucopyranosyl 
trichloroacetimidate (9) 
 
 
O
BnO
BnO
BnO
O
N3
CCl3
CH2Cl2 dry, RT, 
overnight(8)
O
BnO
BnO
BnO
OH
N3
(9)
K2CO3
NH
 
Compound P(g) V(ml) d(g/ml) PM mmol Eq 
(8) 0.20   475 0.42 1 
Trichloroacetonitrile 0.58 404 µl 1.44 144.39 4.03 9.6 
K2CO3 0.17   138.21 1.26 3 
CH2Cl2 dry  3.6     
Theoretical (9) 0.26   618 0.42  
 
Compound (8) (0.200 g, 0.42 mmol) was dissolved in dichloromethane dry (3.6 ml). 
Trichloroacetonitrile (404 µl, 4.03 mmol) and potassium carbonate (0.17 g, 1.26 mmol) 
were added and the reaction mixture was stirred under argon overnight before being 
filtered through celite and concentrated. The residue was chromatographed on silica 
column with ethyl acetate/petroleum ether 1/9 with 1% TEA to afford 0.2 g of 
compound (9). Yield: 77%. 
 
TLC ETP/AcOEt 8/2 Rf (9) = 0.54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(9)
(8)
(8) RX
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6-azido-6-deoxy-2,3,4-tri-O-benzyl β-D-glucopyranosyl 
trichloroacetimidate (9) 
 
 
O
BnO
BnO
BnO
O
N3
(9)
CCl3
NH
 
 
 
 Colourless oil 
 Mol. Wt. = 619.9 
 Exact mass = 618.1 
 C29H29O5N4Cl3 
 1H NMR (500MHz, CDCl3) : δ = 3.31-3.82 (m, 6H, H-2, H-3, H-4, H-5 and 
2H-6), 4.59 – 5.02 (3 d, 6 H, J = 10.8 Hz, CH2Ph) 5.88 (d, 1 H, J1,2 = 7.4 Hz, H-
1), 7.25-7,39 (m, 15 H arom.), 8.78 (s, 1H, NH) ppm. 
 13C NMR (CD3OD):  = 50.88, 74.91, 75.13, 75.30, 75.60, 77.2, 77.57, 80.85, 
84.37, 97.81,127 -129 (15 C), 137.65, 137.80, 138.24, 160.95 ppm. 
 ESI-MS (positive-ion mode) : m/z = 641.0 (100) [M + Na]+, 1260.7 (17) [2M + 
Na]+ 
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Synthesis of Allyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside (11) 
 
 
O
AcO
AcO
OAc
OAc
O
AcO
AcO
O
OAc
1)Allyl alcohol
2)BF3Et2O
DCM dry; RT; 3 h
(10) (11)
AcO AcO
 
Compound P(g) V(ml) d(g/ml) M.W. mmol Eq 
(10) 6   390.27 15.37 1 
Allyl alcohol  2.51 0.852 58.08 36.91 2.4 
BF3Et2O  5.79 1.13 141.93 46.11 3 
CH2Cl2 dry  39     
Theoretical (11)  5.96   388 15,37  
 
Boron trifluoride di-ethyl etherate (5.79 ml, 46,12 mol) was added dropwise to a 
solution of compound (10) (6 g, 15.37 mol) and allyl alcohol (2.51 ml, 36.90 mol) in 
dry dichloromethane (39 ml) at 0 °C. The ice bath was removed after 0.5 h, and the 
reaction was allowed to warm to room temperature until the starting material had been 
consumed (monitored by TLC). The reaction mixture was quenched with a aqueous 
saturated sodium bicarbonate solution (200 ml), extracted with dichloromethane (3*50 
ml), and the combined organic layer were washed with Brine(2*100 ml). Drying 
(Na2SO4) and evaporation of the solvent gave a crude residue that was purified on flash 
column chromatography with ethyl acetate/petroleum ether 4/6 to afford 4.17 g of 
compound (11). Yield : 70%. 
 
TLC AcOEt/ETP 5/5 Rf (11) = 0.52 
 
(11)
(10)
(10) RX
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Allyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside (11) 
 
 
O
AcO
AcO
O
OAcAcO
(11)
 
 
 
 Amorphous solid 
 Mol. Wt. = 388.4 
 Exact mass 388.1 
 C17H24O10 
 This product has been characterised by comparison of its physical data ( [α]D, 
1H NMR, 13C NMR) with that reported in (Kishida et al., 2005) 
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Synthesis of Allyl -β-D-galactopyranoside (12) 
 
 
O
AcO
AcO
O
OAc
O
HO
OH
O
OH
1)MeONa
MeOH dry,
 0°C to RT overnight(11) (12)
AcO HO
 
 
Compound P(g) V(ml) d(g/ml) M.W. mmol Eq 
(11) 3.82   388 9.84 1 
MeONa sol 1 M  19.6   19.69 2 
MeOH dry  78.8     
Theoretical (12) 2.16   220 9.84  
 
 
An ice-cold solution of compound (11) (3.82 g, 9.84 mmol) in dry MeOH (78.8 ml) 
was treated with a freshly prepared solution of sodium methoxide in methanol (19.6 ml 
sol 1M). The ice bath was removed after 0.5 h, and the reaction was allowed to warm 
to room temperature and stirred overnight. The reaction mixture was quenched with an 
ion exchange resin (Dowex Marathon C – H+ form). The resin was filtered off and the 
filtrate was concentrated under vacuum to obtain 2.15 g of compound (12), Yield 99%. 
Compound (12) was used in the next step without further purification. 
 
TLC AcOEt/ETP 5/5 Rf (12) = 0                   TLC AcOEt/MeOH 9/1 Rf (12) = 0.25 
(11)
(12)
(11) RX (11) RX
(11)
(12)
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Allyl-β-D-galattopyranoside (12) 
 
 
O
HO
OH
O
OH
(12)
HO
 
 
 
 Amorphous solid 
 Mol. Wt. = 220.2 
 Exact mass 220.1 
 C9H16O6 
 This product has been characterised by comparison of its physical data ( [α]D, 
1H NMR, 13C NMR) with that reported (Dasgupta et al., 1994). 
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Synthesis of Allyl 2,3,6-tri-O-benzoyl-β-D-galactopyranoside (13) 
 
O
HO
OH
O
OH
O
BzO
BzO
O
OBz
1)Benzoyl chloride
 -30 °C, 0.5 h
(12) (13)
HO HO
2) Pyridine dry
 
Compound P(g) V(ml) d(g/ml) M.W. mmol Eq 
(12) 0.15   220 0.68 1 
Benzoyl chloride  
0.356 in 
5 ml of 
Py dry 
1.21 140.57 3.07 4.5 
Py dry  5     
Theoretical (13) 0.36   532 0.68  
 
A solution of benzoyl chloride in pyridine (356 µl, 3.07 mmol) was added dropwise to 
a solution of compound (12) (0.15 g, 0.68 mmol) in dry Pyridine (5 ml) at -30 °C. After 
0.5 h the reaction mixture was quenched with an aqueous saturated sodium bicarbonate 
solution (200 ml), extracted with dichloromethane (3*50 ml), and the combined 
organics were washed with Brine (2*100 ml). Drying (Na2SO4) and evaporation of 
dichloromethane gave a crude residue that was chromatographed first with 
toluene/ethyl acetate 8/2, to remove the allyl 2,3,4,6-tetra-O-benzoyl-β-D-
galattopyranoside, and then with hexane/ethyl acetate 75/25  to afford 0.181 g of 
compound (13). Yield : 50%. 
 
TLC toluene/ethyl acetate 8/2 Rf (13) = 0.51             
(13)
(12)
(12) RX
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Allyl 2,3,6-tri-O-benzoyl-β-D-galactopyranoside (13) 
 
 
O
BzO
OBz
O
OBz
(13)
OH
 
 
 
 Amorphous solid 
 Mol. Wt. = 532.5 
 Exact mass = 532.2 
 C30H28O9 
 1H NMR (500MHz, CDCl3): δ = 2.60 (d, 1 H, J = 5.4 Hz, OH), 4.09 (dd, 1 H, 
J4,5 = J5,6 = 6.5 Hz, H-5), 4.16–4.23 (m, 1 H, OCHaHbCH=CH2), 4.34-4.43 (m, 
2 H, OCHaHbCH=CH2 and H-4), 4.65 (dd, 1 H, J5,6a = 6.5, J6a,6b = 11.4 Hz, H-
6a), 4.72 (dd, 1 H, J5,6b = 6.5, J6a,6b = 11.4 Hz, H-6b), 4.81 (d, 1 H, J1,2 = 7.9 Hz, 
H-1), 5.11-5.17 (m, 1 H, CH=CHaHb), 5.21-5.27 (m, 1 H, CH=CHaHb), 5.38 
(dd, 1 H, J2,3 = 10.3, J3,4 = 3.2 Hz, H-3), 5.77–5.89 (m, 2 H, CH=CH2 and H-2), 
7.36–7.64 (m, 10 H, arom.), 7.96–8.12 (m, 5 H, arom.) ppm. 
 13C NMR (CD3OD):  = 62.7, 67.3, 69.6, 69.9, 72.3, 74.2, 100.1, 117.7, 128.3 – 
133.5 (19 C), 165.3, 165. 9, 166.4. 
 []D20 = + 56.5 (c = 1 in chloroform) 
 ESI-MS (positive-ion mode) : m/z = 555.1 (52) [M + Na]+, 1087.0 (100) [2M + 
Na]+ 
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Syntesis of Allyl 6-azido-6-deoxy-2,3,4-tri-O-benzyl--D-
glucopyranosyl-(1→4)-2,3,6-tri-O-benzoyl-β-D-galactopyranoside (14) 
 
OBnO
BnO
BnO
N3
O
O
BzO
BzO
O
OBz
O
HO
BzO
BzO
OBz
O
OBnO
BnO BnO
O
N3
NH
CCl3
(9)
(13)
(14)
2)TMSOTf
1)MS 4 Å
Et2O dry, - 40 °C, 
0.5 h
 
Compound P(g) V(ml) d(g/ml) P.M. mmol Eq 
(9) 1,63   618.1 2.64 2 
(13) 0.70   532.1 1.32 1 
Sol. 0.1 M 
TMSOTf  2.56   0.26 0.2 
MS 4 Å 1.63      
Et2O dry  40     
Theoretical (14)  1.30   989.1 1.32  
 
Trimethylsilyl trifluoromethansulfonate (2.56 ml, sol 0.1M) was added dropwise to a 
cooled solution  of compound (9) (1.63 g, 2.64 mmol), compound (13) (0.70 g, 1.32 
mmol) and molecular sevies 4 Å (1.63 g) in dry diethyl ether (40 ml). The reaction 
mixture was quenched after 0.5 h with a solid sodium bicarbonate before being filtered 
through celite and concentrated. The residue was chromatographed on silica column 
with ethyl acetate/hexane 15/85 to afford 0.69 g of compound (14). Yield: 53%. 
 
TLC AcOEt/Hex 15/85 Rf (14) = 0.36 
(9)
(13)
(9) RX X(13)
(14)
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Allyl 6-azido-6-deoxy-2,3,4-tri-O-benzyl--D-glucopyranosyl-(1→4)-
2,3,6-tri-O-benzoyl-β-D-galactopyranoside (14) 
 
 
O
BnO
BnO
BnO
N3
O
O
BzO
BzO
O
OBz
(14)
 
 
 
 
 Amorphous solid 
 Mol. Wt. = 990.1 
 Exact mass = 989.4 
 C57H55O13N3 
 1H NMR (500MHz, CDCl3):  = 3.14–3.25 (m, 2 H, 2 H-6’), 3.52 (dd, 1 H, J1’,2’ 
= 3.4, J2’,3’ = 9.8 Hz, H-2’), 3.61 (dd, 1 H, J3’,4’ = J4’,5’ = 9.6 Hz, H-4’), 4.05 (t, 1 
H, J4’,5’ = J5’,6’ = 6.6, H-5’), 4.13–4.25 (m, 3 H, H-3’, H-5’ and 
OCHaHbCH=CH2), 4.36–4.43 (m, 2 H, H-4 and OCHaHbCH=CH2), 4.58–4.78 
(m, 6 H, 2 H-6, H-1, 3 CH2Ph), 4.88 (d, 1 H, J1’,2’ = 3.4 Hz, H-1’), 4.92-5.06 (m, 
3 H, 3 CH2Ph), 5.10–5.15 (m, 1 H, CH=CHaHb), 5.20-5.27 (m, 1 H, 
CH=CHaHb), 5.29 (dd, 1 H, J2,3 = 10.6, J3,4 = 2.9 Hz, H-3), 5.73 (dd, 1 H, J1,2 = 
7.8, J2,3 = 10.6 Hz, H-2), 5.78-5.88 (m, 1 H, CH=CH2), 7.11–7.65 (m, 24 H, 
arom), 7.93–8.09 (m, 6 H, arom) ppm. 
 13C NMR (CDCl3):  = 50.68, 63.0, 69.7, 70.0, 71.1, 72.8, 73.8, 74.0, 75.1, 
75.6, 76.0, 77.9, 80.2, 80.2, 81.4, 99.9, 100.1, 117.8, 127.6–133.6 (33 C), 137.9, 
138.3, 138.7, 165.4, 166.1, 166.2 ppm. 
  []D20 = + 94.3 (c = 1 in chloroform) 
 ESI-MS (positive-ion mode) : m/z = 1012.3 (100) [M + Na]+ 
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Synthesis of  6-azido-6-deoxy-2,3,4-tri-O-benzyl--D-glucopyranosyl-
(1→4)-2,3,6-tri-O-benzoyl-D-galactopyranoside (15) 
 
OBnO
BnO
BnO
N3
O
O
BzO
BzO
OH
OBz
(15)
OBnO
BnO
BnO
N3
O
O
BzO
BzO
O
OBz
(14)
THF dry, RT, 3 h
1)NBS
2)THF, H2O
RT, 30 min
Ir(C9H12)[PMePh2]2PF6
1° step
2° step
 
Compound P(g) V(ml) d(g/ml) P.M. mmol Eq 
(14) 0.67   989.4 0.68 1 
Ir(C9H12)[PMePh2]2PF6 0.017 
3.7 di 
THF 
dry 
 845.79 0.02 0.03 
THF dry  15.7     
NBS 0.18   177.99 1.02 1.5 
H2O  2.27     
THF  34.9     
Theoretical (15)  0.645   949 0.68  
 
To a solution of compound (14) (0.67 g, 0.68 mmol) in THF dry (15.7 ml) was added 
dropwise under anhydrous condition at RT a solution of Ir catalyst (17 mg, 0.0203 
mmol in 3.7 ml THF dry), previously activated with  hydrogen for 0.5 h, under 
anhydrous condition at RT, then the reaction mixture was stirred for 3 h at RT. After 
this time NBS (0.18 g, 1.02 mmol), water (2.27 ml) and THF (34.9 ml) were added and 
the reaction mixture was stirring for 0.5 h, then the THF was removed under vacuum.  
The residue was diluted with ethyl acetate (100 ml), washed with a aqueous saturated 
sodium bicarbonate solution (100 ml) and Brine(2*100 ml). Drying (Na2SO4) and 
evaporation of the ethyl acetate layer gave a crude 
residue that was chromatographed on silica column 
with ethyl acetate/petroleum ether 2/8 to afford 0.445 g 
of  compound (15). Yield: 71%. The identity of the 
compound was assessed through MS experiment. 
Compound (15) was used in the next step without 
further characterization. 
 
TLC AcOEt/ETP 5/5 Rf  (15) = 0.4 
(14)
(15)
(14) RX
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6-azido-6-deoxy-2,3,4-tri-O-benzyl--D-glucopyranosyl-(1→4)-2,3,6-
tri-O-benzoyl-D-galactopyranoside (15) 
 
 
O
BnO
BnO
BnO
N3
O
O
BzO
BzO
OH
OBz
(15)
 
 
 
 Amorphous solid 
 Mol. Wt. = 950 
 Exact mass = 949.3 
 C54H51O13N3 
 ESI-MS (positive-ion mode) : m/z = 972.3 (100) [M + Na]+, 1921.3 (12) 
[2M + Na]+  
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Synthesis 6-azido-6-deoxy-2,3,4-tri-O-benzyl--D-glucopyranosyl-
(1→4)-2,3,6-tri-O-benzoyl--D-galactopyranosyl trichloroacetimidate 
(16) 
 
 
OBnO
BnO
BnO
N3
O
O
BzO
BzO
OH
OBz
(15)
OBnO
BnO
BnO
N3
O
O
BzO
BzO
OBz
O
NH
CCl3
(16)
1) NCCCl3
2) DBU
CH2Cl2 dry, RT, 3 h
 
Compound P(g) V(ml) d(g/ml) PM mmol Eq 
(15) 0.445   949.3 0.468 1 
Trichloroacetonitrile 0.649 450 µl 1.44 144.39 4.500 9.6 
DBU  5 µl     
CH2Cl2 dry  5     
Theoretical (16)  0.511   1092 0.468  
 
Compound (15) (0.445 g, 0.468 mmol) was dissolved in CH2Cl2 dry (5 ml). 
Trichloroacetonitrile (0.450 ml, 4.500 mmol) and DBU (5µl) were added and the 
reaction mixture was stirred under argon for 3 h before being filtered through celite and 
concentrated. The residue was chromatographed on silica column with ethyl 
acetate/petroleum ether 2/8 with 1% TEA to afford 0.408 g of compound (16). Yield: 
80%. 
TLC AcOEt/ETP 5/5 Rf (16) = 0.46 
 
 (16)
(15)
(15) RX
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6-azido-6-deoxy-2,3,4-tri-O-benzyl--D-glucopyranosyl-(1→4)-2,3,6-
tri-O-benzoyl--D-galactopyranosyl trichloroacetimidate (16) 
 
 
O
BnO
BnO
BnO
N3
O
O
BzO
BzO
OBz
O
NH
CCl3
(16)
 
 
 
 Colourless oil 
 Mol. Wt. = 1094.2 
 Exact mass = 1092.3 
 C56H51O13N3Cl3 
 1H NMR (500MHz, CDCl3):  = 3.07 – 3.17 (m, 2 H, 2 H-6’), 3.55 (dd, 1 H, 
J1’,2’ = 3.3, J2’,3’ = 9.8 Hz, H-2’), 3.61 (dd, 1 H, J3’,4’ = J4’,5’ = 9.5 Hz, H-4’), 
4.11–4.23 (m, 2 H, H-3’ and H-5’), 4.56 (d, 1 H, J3,4 = 2.6 Hz), 4.58–4.83 (m, 6 
H, H-5, 2 H-6, 3 CH2Ph), 4.89 (d, 1 H, J1’,2’ = 3.4 Hz, H-1’), 4.92–5.11 (m, 3 H, 
3 CH2Ph), 5.82 (dd, 1 H, J2,3 = 10.9, J3,4 = 2.6 Hz, H-3), 5.94 (dd, 1 H, J1,2 = 3.7, 
J2,3 = 10.9 Hz, H-2), 6.80 (d, 1 H, J1,2 = 3.7 Hz, H-1), 7.10–7.65 (m, 24 H, 
arom), 7.92–8.06 (m, 6 H, arom), 8.59 (s, 1 H, NH) ppm 
 13C NMR (CDCl3):  = 50.7, 63.1, 67.5, 70.5, 71.2, 71.6, 74.3, 75.2, 75.6, 76.2, 
77.2, 78.0, 80.1, 81.4, 94.0, 99.7, 127.6-130.0 (30 C), 133.2, 133.4, 133.6, 
137.7, 138.1, 138.5, 160.6, 165.5, 165.9, 166.0.  
 []D20 =  + 121.1 (c = 1 in chloroform) 
 ESI-MS (positive-ion mode) : m/z = 1115.0 (100) and 1116.9 (96) [M + 
Na]+ 
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Synthesis of 18-Pentatriacontanyl 6-azido-6-deoxy-2,3,4-tri-O-benzyl-
-D-glucopyranosyl-(1→4)-2,3,6-tri-O-benzoyl--D-galactopyranoside 
(17) 
 
OBnO
BnO
BnO
N3
O
O
BzO
BzO
OBz
O
NH
CCl3
(16)
1)AW 300, 0.5 h
2)TMSOTf
CHCl3 dry, RT, 0.5 h
OBnO
BnO
BnO
N3
O
O
BzO
BzO
OBz
O
C16H33
C16H33
(17)
HO
C16H33
C16H33
 
Compound P(g) V(ml) d(g/ml) PM mmol Eq 
(16) 0.330   1092.3 0.302 1 
18-Pentatriacontanol 0.230   508.6 0.453 1.5 
MS AW-300 2.44      
CHCl3 dry*  13.5     
Sol. 0.1 M TMSOTf  0.6   0.060 0.2 
Theoretical (17)  0.434   1439.9 0.302  
* Chloroform was treated with calcium chloride under argon overnight to remove the presence of 
ethanol,  then was filtered and through on alumina column, to remove the presence of acidity, and finally 
dried on MS 4 Å. 
 
A solution of compound (16) (0.330 g, 0.302 mmol), 18-pentatriacontanol (0.230 g, 
0.453 mmol) and MS AW300 (2.44 g) in chloroform dry (13.5 ml) was stirred for 0.5 h 
a RT under argon, and than cooled to 0 °C. Trimethylsilyl trifluoromethansulfonate 
(0.6 ml) was added and the stirring was continued for 0.5 h at RT. The reaction mixture 
was quenched with TEA and solid were filtred off with celite and washed with 
chloroform. The organic layer was concentrated, the excess of alcohol was cristallized 
with Et2O and separated by filtration.The organic layer 
was concentrated and the crude was chromatographed 
on silica column with n-hexan/dichloromethane/ethyl 
acetate  8.5/1/0.5 to afford 0.364 g of  compound (17). 
Yield: 83 %. 
 
TLC Hex/CH2Cl2/AcOEt 8.5/1/0.5 Rf (17) = 0.47 
(17)
(16)
(16) RX
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18-Pentatriacontanyl 6-azido-6-deoxy-2,3,4-tri-O-benzyl--D-
glucopyranosyl-(1→4)-2,3,6-tri-O-benzoyl--D-galactopyranoside (17) 
 
 
O
BnO
BnO
BnO
N3
O
O
BzO
BzO
OBz
O
C16H33
C16H33
(17)
 
 
 Colourless oil 
 Mol. Wt. = 1440.9 
 Exact mass = 1439.9 
 C89H121O13N3 
 1H NMR (500MHz, CDCl3) :  = 0.73–1.76 (m, 70 H, aliphatic), 3.12–3.26 (m, 
2 H, 2 H-6’ ), 3.47–3.66 (m, 3 H, H-2’, H-4’ and OCH), 4.03 (t, 1H, J4,5 = J5,6 = 
6.3 Hz, H-5), 4.14-4.26 (m, 2 H, H-3’, H-5’), 4.37 ( d, 1 H, J3,4 = 2.6 Hz, H-4), 
4.57 – 4.82 (m, 6 H, H-1, 2 H-6 and 3 CH2Ph), 4.87 (d, 1 H, J1’,2’ = 3.4 Hz, H-
1’), 4.90 – 5.07 (m, 3 H, 3 CH2Ph), 5.29 (dd, 1 H, J2,3 = 10.7, J3,4 = 2.6 Hz, H-3), 
5.67 (dd, 1 H, J2,3 = 10.7, J1,2 = 7.8 Hz, H-2), 7.10-7.64 (m, 24 H, arom), 7.91-
8.09 (m, 6 H, arom) ppm. 
 13C NMR (CD3OD):  = 14.1, 22.7 – 35.0 (33 C), 50.7, 63.3, 70.0, 71.0, 72.7, 
73.9, 74.0, 75.1, 75.6, 76.2, 78.0, 80.3, 81.4, 82.4, 99.9, 101.7, 127.6 – 129.9 
(30 C), 133.0, 133.1, 133.5, 138.0, 138.3, 138.7, 165.2, 166.1, 166.2. 
 []D20 = + 79.1 (c = 1 in chloroform) 
 ESI-MS (positive-ion mode) : m/z = 1463.7 (100) [M + Na]+, 1478,7 (33) [M + 
K]+ 
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15. CONCLUSION 
 
The aim of this work was to prepare a fluorescent analogue of simplexide to evaluate 
the subcellular distribution of the glycolipid and to clarify its mechanism of action. 
The synthetic approach has been develop in order to obtain fluorescent simplexide 
through glycosylation between the preformed activated disaccharide (14) and the lipid 
moiety. The disaccharide in turn was obtained by glycosylation  between a glucosyl 
donor (9) selectively functionalized with an azido group at position 6 and a galactoside 
acceptor(13). 
The galactoside acceptor was achieved in a few steps for the reason that we used a 
protocol for selective benzoylation, at low temperature, that allowed us to avoid tedians 
step of protection and deprotection of the hydroxyl group to obtain the final product. 
Furthermore, several studies have been conducted on the reaction of glycosylation  
between the two sugar moieties as reported in the table 3.  
Table 3 . Study of glycosilation between the glucosyl donor and galactosyl acceptor. 
 
GLUCOSYL DONOR GALACTOSYL ACCEPTOR CONDITION (1 h) 
YELD OF (14) 
(%) 
 
 
(9) 
 
 
 
 
 
(13) 
 
 
 
TMSOTf / DCM / -40 °C 25 
TMSOTf / DCM / -40 °C / MS 4 Å 25 
TMSOTf / DCM / 0°C  15 
TMSOTf / THF / -40 °C < 5 
TMSOTf / THF / 0 °C  < 5 
TMSOTf / Et2O / -40 °C / MS 4 Å  55 
BF3Et2O / Et2O / -40 °C / MS 4 Å < 10 
BF3Et2O / DCM / -40 °C < 10 
TESOTf / DCM / -40 °C  20 
 
We tried different conditions and finally we were able to select a protocol that has 
allowed us to obtain, using dry diethyl ether as the solvent and a solution of 
trimethylsilyl trifluoromethansulfonate as the catalyst, disaccharide (14) in good yields 
and high selectivities. 
 In addition, the dissaccaride (14), after activation of anomeric position, was 
glycosylated with a long chain alcohol to obtain the intermediate (17) in very 
satisfactory yield if compared to the few examples described in the literature.  
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16. FUTURE AND PROSPECTIVE 
 
Starting from compound (17) the synthesis of final product (1) will be carried out using 
standard deprotection procedures, to remove the protective groups, then will be 
reduced the azido group, through Staudinger reaction, to obtain the corresponding 
amine which finally will be combined with the flourescent probe. 
This compound will be used for study of subcellular distribution and also to clarify the 
mechanism of action of simplexide. 
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17. LIST OF ABBREVIATIONS  
 
AAG   1-O-alkyl-2-O-acyl-sn-glycerol 
AcOEt                         Ethyl Acetate  
AMPs                         Antimicrobial peptides 
APC                            Antigen presenting cell 
APM                           Anterior plasma membrane  
AR                              Acrosome reaction 
ASA    Arylsulfatase A 
BF3Et2O                     Boron trifluoride di-ethyl etherate 
BSA   Bovine serum albumin 
CAD                           Collisionally activated dissociation 
CAMP                        Cathelicidin antimicrobial peptide gene 
cAMP   Cyclic adenosine monophosphate 
CGT   Ceramide galactosyltransferase 
CHO                           Chinese hamster ovary cells 
CMV                           Ciìytomegalovirus 
CST   Cerebroside sulfotransferase 
DCM                           Dichloromethane 
DBU                           1,8-diazabiciclo[5.4.0]undec-ene 
DMF                           N,N-dimethylformamide 
ECL   Enhanced chemiluminescence 
EDTA   Ethylenediaminetetraacetic acid 
ELISA   Enzyme-linked immunosorbent assay 
ER                               Endoplasmic reticuli 
ESI                              Electrospray ionization 
ETP                             Petroleum Ether 
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FMP                            Forward motility protein 
FRLP-1                       Formyl peptide receptor-1 
GC  galactosylceramide 
GG galactosylglycerolipid 
hCG                            Human chorionic gonadrotropin 
HIV   Human immunodeficiency virus 
HPTLC  High performance thin layer chromatography 
HTF                            Human tubal  fluid 
HTF-HEPES              HEPES-buffered Human tubal fluid        
HRP   Horseradish peroxidase 
HSP                            Heat shock protein 
IB                                 Immunoblotting 
IgG    Immunoglobulin G 
IIF    Indirect immunofluorescence 
IL                                 Interleukine 
KRB                            Krebs Ringers bicarbonate 
KRB-HEPES              HEPES-buffered Krebs Ringers bicarbonate 
LTB4                          Leukotriene B4  
LPS                             Lipopolysaccharide 
MeOH                         Methanol 
MeONa                       Sodium Methoxyde 
MLD                           Metachromatic leukodystrophy  
MS   Mass spectrometry 
MS                              Molecular sevies 
NBS                            N-bromosuccinimide 
mZP                            mouse zona(e) pellucida(e) 
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NMR   Nuclear magnetic resonance 
NK                              Natural killer cells 
OPD   o-phenylenediamine dihydrochloride 
PAP   3’-phosphoadenosine-5’-phosphate 
PAPS   3’-phosphoadenosine-5’-phosphosulfate 
PBMC                         Peripheral blood mononuclear cell 
PBS   Phosphate-buffered saline 
PC   3-sn-glycerophosphorylcholine 
PGC   Percoll gradient centrifuged 
PKA   Protein kinase A 
PMSG                         Pregnant Mare Serum Gonadrotropin 
PS   3-sn-glycerophosphorylserine 
PUFA                          Polyunsaturated fatty acid 
Py                                Pyridine 
PVP                             Polyvinylpyrrolidone 
RT                                Room temperature 
SDS   Sodium dodecyl sulfate 
SDS-PAGE  Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SGC sulfogalactosylceramide 
SGG  seminolipid 
STD                            Sexual transmitted disease 
STI                              Sexual transmitted infectious 
TBAI                           Tetra-n-butylammoniun iodide 
TBS   Tris-buffered saline 
TEA                            Triethylammine 
TLC   Thin layer chromatography 
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TMSOTf                     Trimethylsilyl trifluoromethansulfonate 
TNF-α                         Tumor necrosis factor-alpha 
UDP   Uridine diphosphate 
UDP-Gal  Uridine diphosphate galactose 
X                                 Molar ratio 
WHO                          Word Healt Organizzation 
ZP    Zona(e) pellucida(e)  
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